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1. Introduction 
 
Despite their microscopic appearance that belies their functional heterogeneity and 
development, lymphocytes known as T (thymus derived) and B cells (bursa or bone marrow 
derived) have boosted the curiosity and challenged the experimental skills in many 
disciplines. A simplified definition of B cells is a population of cells expressing clonally 
diverse cell surface immunoglobulin (Ig) receptors which recognize specific antigenic 
epitopes having their functional end point in antibody production by terminally differentiated 
plasma cells (LeBien et al, 2008). The discovery and characterization of B cells occurred in 
mid 1960s and early 1970s using animal models by cellular surface molecule characterization 
(Good et al, 1956, Cooper et al, 1965, 1966). 
 
1.1 B-cell development in Human 
B cell development begins in the fetal liver and continues in the bone marrow 
throughout our lives. Lymphoid progenitors are descendant of hematopoietic stem cells 
(HSCs) with ability to develop into all lymphohematopoietic lineages. These lymphoid 
progenitor cells receive signals from bone marrow stromal cells through cell-cell contacts and 
secreted signals. This bone marrow microenvironment is responsible for B cell development 
where B cell precursors start development in bone marrow which later on migrates to 
peripheral lymphoid organs for becoming mature naïve B cell which continuously circulate in 
lymphoid tissue and blood until encounter an antigen. Once binding antigen to BCR (B cell 
receptor), this complex (antigen: BCR) is internalized, processed and presented as an antigen-
MHC class II complex to T cells. This antigen specific T cell causes co-stimulation of the B 
cell which further develops into a memory B cell or plasma cells to be a continuous source of 
antibody production (LeBien, 2000; LeBien et al, 2008; Janeway et al, 2005). 
 
 
1.1.1 B cell ontogeny 
The earliest lineage of B cells is termed pro B cells in which heavy chain gene 
segments rearrangement takes place. During further differentiation of pro B cell, 
rearrangement of VH segment to DHJH-rearranged segments of IgH chain occurs. The 
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recombinase-activating genes, RAG-1 and RAG-2, play a fundamental role in these events 
(kawano et al, 2006). RAG-1 and RAG-2 enzymes are very crucial in development of the 
BCR and without these enzymes no lymphocytes can develop. A productive VDJH joining 
leads to the next B cell development stage called Pre B cell stage. 
During Pre B cell stage, µH chains produced in early phase combines with invariant 
VpreB/y5 surrogate light to form the pre-B cell receptor. Pre BCR provides a signal to 
proceed with light chain rearrangement. If the B cell fails to express the receptor ultimately 
causes cell apoptosis. Thus the pre BCR formation serves as checkpoint for positive selection 
of Pro B cells (Karasuyama et al, 1996; Kawano et al, 2006).Upon light chain rearrangement 
complete IgM molecule is expressed on cell surface which becomes Immature B cell (Fig. 
1.1). 
An Immature B cell expressing surface IgM if binds strongly to self molecules is 
directed to die by apoptosis. Alternatively, the cell gets survival chance through receptor 
editing of IgM molecule and if this is successful the cell survives. 
Finally the B cell that does not bind self molecule continue its journey as transitional 
B cell by expressing both IgM and IgD on its surface and develop into a naïve mature B cell 
and migrates through blood to the peripheral lymphoid organs where final maturation occur 
where B cell is again tested for its self-reactivity. 
 
1) If it strongly binds self-antigen that ultimately cause cell death by apoptosis due to receptor 
cross linking.  
2) Soluble self antigen which does not cross link the receptor cause cell anergy and ultimately 
the cell dies. If the cell survives this final test, it is ready to patrol for antigens (Janeway et al, 
2005). 
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Figure: 1.1 The steps of B cell development: involving checkpoints for generation of productive 
immunoglobulin gene rearrangement (Adopted from Immunobiology; Janeway et al, 2005) 
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1.2 B cell activation 
 
Mature B cells and their products, mainly antibodies, constitute the backbone of 
humoral immunity in protecting extracellular spaces from pathogenic invasions. As mature 
naïve B cells patrol in the blood and lymphoid follicles of spleen and lymph nodes until 
encounter of invading antigens or the antigenic binding to B cell receptor (BCR). The BCR is 
composed of an immunoglobulin antigen binding unit which is associated with Igα/Igβ 
heterodimers which function as signal transduction unit and provide a connection of BCR to a 
well organized complex of cytoplasmic signalling molecules (Fig.1.2). This binding provides 
first B cell activation signal which also require a secondary signal for fully activation, this 
signal is provided either by T cells dependent or independent ways (Carsetti et al, 2001). 
 
 
 
 
 
 
 
 
 
 
Figure 1.2 Cell membrane IgM on the surface of mature B cell is associated with Igα and Igβ molecules. 
The resulting complex constitutes the B cell antigen receptor complex. Igα and Igβ contain ITAMs in their 
cytoplasmic tails that mediate signal transduction (Adapted from Vasile et al, 1994). 
 
T cell independent responses (TI) are induced when antigen itself binds to Toll like receptor 
(TLR) on B cell surface or BCR cross linking. Long polysaccharide chain containing antigens 
usually results TI responses. In contrary to TI responses, T cell help is required to induce T 
cell dependent responses. When this signal is induced by T cells, antigen: BCR complex is 
internalized and endosomally processed to present antigen-derived peptides in MHC II on the 
B cell surface where T cell recognize MHC:antigen complex and are activated and upregulate 
CD40L which co-stimulates the activated B cells (Weller et al, 2001). 
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The pathway of B cell functioning is a complex road with multiple factors 
involvement for successful responses. B cells undergo a complex series of genetic events 
including somatic hypermutation, gene conversion and class-switch recombination which are 
now discussed in details. 
 
1.3 Somatic hypermutation 
B cells have a unique ability to fine tune their receptors to creat antigenic specificity in 
order to improve their ability to bind a diverse variety of antigens. This ability of generating 
repertoire diversity is result of somatic hypermutation process which modifies variable 
segment of rearranged immunoglobulin (Ig) genes during an immune response. A distinctive 
difference between naïve and memory B cells is attributed to this process. In primary immune 
responses, Ig genes have germline configuration but numerous point mutations are notable in 
Ig genes of antibodies during secondary immune responses (Longo et al, 2006). The process 
of somatic hypermutation is associated with DNA strand breaks and induction of mostly 
single nucleotide exchange. During this process small deletions and duplications are produced 
in rearranged IgV region at the rate of 10-3 per base pair per generation (Klein et al, 2008). 
 
 
1.3.1 Sites of somatic hypermutation 
Circulating B cells after antigenic stimulation migrate through the helper T cell rich 
areas of secondary lymphoid organs e.g. Spleen and lymph nodes to form germinal centres. B 
cells proliferation occurs in dark zone of GC, while switching of effector functions i-e re-
expression of surface Ig (sIg) and antigenic driven selection occurs in light zone (Liu et al, 
1997). Somatic hypermutation of Ig V genes occurs in dark zone (Figure 1.3) which indicates 
that DNA replication and /or repair mechanisms are involved in the mutational mechanism. 
The enzyme Activation induced cytidine Deaminase (AID) is crucial for the process of 
somatic hypermutation which deaminates cytosine at hotspots within the variable (V) region 
of the immunoglobulin DNA. A mechanistic approach to understand the process of somatic 
hypermutation in addition to involved mechanisms is briefly described below. 
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Figure 1.3 Germinal centre microenvironment: Antigen-activated B cells differentiation and clonal expansion 
in the dark zone of the germinal centre. During proliferation, the process of somatic hypermutation (SHM) 
introduces base-pair changes into the V (D) J region of the rearranged genes encoding the immunoglobulin 
variable region (IgV) of the heavy chain and light chain occurs (adopted from Klein et al, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
Longterm impact of anti-CD20 mediated transient B cell depletion on memory B cells in patients with RA 
 
7 
 
1.3.2 Role of Transcription in somatic hypermutation 
 
The process of Somatic hypermutation is confined to 1-2 kilobase region in the 
rearranged Ig gene and mutations are introduced in regions which encompasses ~2 kb 
downstream of transcriptional region. These mutations are non-random (Klein et al, 2008). 
Several studies have implicated the role of transcription in somatic hypermutation.  
The enhancer/matrix attachment region in JC intron in heavy chain locus is believed to 
be indispensible for this process while 3 prime enhancers which are downstream from C 
exons seem to facilitate somatic hypermutation reaction (Azuma et al, 1994). Replacement of 
Ig promotor with heterogeneous promotor and movement of promotor either to downstream 
or upstream of V region displaces mutations to the regions 3 prime of the promotor (Diaz et 
al, 1998). However deletion of sequences which are upstream of the promotor region does not 
influence the process of hypermutation (Tumas-brundage et al, 1996). As concluding 
remarks, the frequency of mutations increases rapidly in the leader intron peaks at 
rearrangement V (D) J exon and decreases into J-C intron of Ig genes. 
 
1.3.3 DNA double strand breaks and error-prone DNA repair 
  DNA double strand breaks (DSBs) also play important role in inducing somatic 
hypermutation process based on deletion and duplication analysis. This DNA double strand 
breaks occurs in the V gene of Ig genes of GC B cells (Goossens et al, 1998).DSBs could be 
introduced as direct single nucleotide substitutions via base modification mechanism without 
interference with the sugar-phosphate backbone of the DNA double helix (Wu et al, 2003). 
These DSBs enhance a high transcriptional activity and their distribution along VHDJH 
parallels the mutations in hypermutation domain. Mostly DSBs (around 50%) occur at 
RGYW consensus motifs(R=purine, Y= pyrimidine, and W=A or T) which are intrinsic hot 
spots of somatic hypermutations (Bross et al, 2000) indicating that DSBs appears to depend 
on transcriptional activity. 
DSBs are repaired through two competitive pathways which include opposing and 
rejoining broken DNA ends with no or little regard for sequence homology or by template 
directed homologous recombination process. Research has also shown that DSBs in 
hypermutating B cells are mainly done during S/G2 cell populations and mutations are also 
occur during DSB repair by homologous recombination after recruitment of error-prone DNA 
polymerase(Papavasiliou et al, 2000). Error-prone DNA polymerase inserts incorrect bases 
and capable of extension of newly generated mismatched terminus. These error-prone 
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translation or lesion bypass polymerases affect continuous strand synthesis opposite to DNA 
lesions that install a replication fork. Several studies have shown that translation DNA 
polymerases like β, µ, δ, κ and λ are not involved while polymerase ι and ζ play important 
role in somatic hypermutation. Polymerase ι is involved to insert an incorrect base while 
ubiquitous polymerase ζ extends from mismatch repair for stabilizing the mutation (Wu et al, 
2003; Holbeck et al, 1997) 
 
1.3.4 Class-switch recombination 
All mature B cells starting out as IgM+IgD+ and after encountering antigen and CD40-
CD40L interaction they can exchange the IgM and IgD with a receptor of different isotype i-e 
IgA, IgG or IgE  which is facilitated by a process of class switch recombination. Class-switch 
recombination is recombination between two different switch regions which are present 
upstream from each C region of IgH with deletion of the intervening DNA. The DNA 
between switch region of choice get looped out and forms excised intervening DNA. 
Recombination signal for a particular switch region comes from the cell surface. Class 
switching is irreversible recombination of DNA and during this process of exchange constant 
regions of the heavy chains but leaves the variable regions intact (Klein et al, 2008; Longo et 
al, 2006).  
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1.4 Regulation of somatic hypermutation process 
 
Activation induced cytidine Deaminase (AID) enzyme is believed to be a master 
regulator of secondary antibody diversification processes (Figure 1.4) by exerting its 
important role in immunoglobulin somatic hypermutation process and class-switch 
recombination. AID is a 24kDa enzyme which removes the amino group from the cytidine 
base in DNA (Bransteitter et al, 2003). AID is normally expressed in germinal centre B cells but its 
forced expression in B cells at wrong differentiation stage results enhanced mutagenesis and 
mutational spectra mimicking somatic hypermutation. AID expression in non-B cells suggest that its 
operation does not require either B cell specific V gene targeting elements and other normal B cell 
proteins for its natural functioning (Martin et al, 2002). 
AID is believed to initiate process of somatic hypermutation by different multi-step processes 
including catalyzing dC            dU deamination activity on double stranded DNA containing 
small ‘transcription like’ single stranded DNA substrates during somatic hypermutation and 
mutational hotspots RGYW are preferentially deaminated resulting mutations and mismatchs 
which are recognized by mismatch repair machinery  followed by error-prone DNA 
polymerases  (Bransteitter et al, 2003; Poltoratsky et al, 2000) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4 Activation-induced cytidine deaminase (AID): deaminates cytidine residues in DNA to be 
processed either by base excision repair (BER) or mismatch repair (MMR). In somatic hypermutation, the 
mismatch can be replicated to produce a C-to-T mutation, nick processing by UNG can produce an abasic site, or 
a gap can be filled in by error prone polymerases. (Adapted from Nussenzweig et al, 2004) 
Longterm impact of anti-CD20 mediated transient B cell depletion on memory B cells in patients with RA 
 
10 
 
 
1.5 Peripheral B cell pool 
 
After passing highly strict phases during development, successful B cells ultimately 
reach the peripheral Blood. Different B cell subpopulations are identified in blood based on 
surface molecular expression to differentiate them mainly into naïve and memory B cells. Fig. 
1.5 represents all B cell subpopulations in peripheral blood with an average percent presence 
of these populations. Below is phenotypic description of B cells subpopulations and their 
products: 
1) Naïve B cells: CD19+CD20+CD27-CD5+/-IgD+IgM+ 
Naïve mature B cells have not yet encountered antigen. These B cells have unmutated 
V genes and comprise 60% of peripheral B cell pool. Majority of naïve B cells are CD5 
negative but small fraction is CD5+ (~15%).CD5- B cells are precursors of GC-B cells in T 
cell dependent immune responses while CD5+ B cells are believed to not involve in T cell 
dependent responses (Klein et al, 1998). 
2) Memory B cells: CD19+CD20+CD27+IgD+/- or IgG+, IgA+, IgM+ or IgE+ 
Memory B cells are mature B cells who have encountered antigen and have 
somatically mutated Ig receptors.CD27 is representative key surface marker to differentiate 
memory B cells from naïve population (Agematsu et al, 2000). More recently in patients 
suffering from autoimmune disease SLE (systemic lupus erythematosus) have shown CD27-
/IgD- cells have been identified displaying features of memory B cells ( Wei et al,2007; 
Jacobi et al, 2008). Human memory B cells are mainly distinguished into post-switched 
memory B cells (IgD-CD27+ cells) and pre-switched (IgD+CD27+ cells) memory B cells. 
Post-switched memory B cells under maturation process in classical germinal centers in 
secondary lymphoid organs(Klein et al,1998) but very little is known about the origin of 
IgD+CD27+ memory B cells.  
3) Plasmablasts (CD19+CD20+CD27+CD38+++CD138- B cells) and Plasma cells: CD19-CD20-
CD27+CD38++CD138+ B cells 
Plasma cells are factories of soluble antibodies production. These include both short 
and long lived plasma cells. Short lived plasma cells survive for few days while long lived 
plasma cells can survive for months. Plasma cells are believed to survive and reside in so 
called survival niches in bone marrow, inflammatory sites and secondary lymphoid organs 
(Radbruch et al, 2006) 
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Figure 1.5 The PB B cell pool and its presumptive generation: Different subpopulations of human B cells in 
peripheral blood (adopted from Klein et al, 1998) 
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4) Antibodies 
The main product of B cell immune responses are antibodies which circulate in blood 
stream which are main responsibility of plasma cells. Structurally, an antibody consists of 4 
protein chains: 2 light chains and 2 heavy chains. Each chain consists of a constant portion 
which is involved in isotype determination and a variable part V which constitutes the antigen 
binding site. The figure 1.6 shows antibody structure. In human, V region from light chain 
could be either Vκ or Vλ while V region of heavy chain has 6 sub-genes (VH1-VH6) which 
provide diversity in VDJ recombination process and variety of antibodies .There are 5istypes 
of antibodies known as IgD, IgG, IgM, IgA and IgE. In human, IgA and IgG are further 
divided into subclasses IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4 (Janeway et al, 2005)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 A schematic diagram of antibody: showing constant CH and variable regions V. 
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1.6 Regulators of B cells 
 
Among many regulators of B cells during formation, certain cytokines are very important for 
B cell maturation and normal functioning .These cytokines play central role in B cells. A short 
description of few cytokines is described below. 
 
 
BAFF 
Most of cells die in absence of appropriate survival signals and growth factors. B cell 
activating factor is fundamental survival factor of B cells. BAFF belongs to TNF family and 
is crucial for B cell maturation. BAFF mRNA is present in monocytes, macrophages, 
dendritic cells and by growth factor-stimulated neutrophils. Very low expression is observed 
in T cells but completely absent in B cells (Schneider et al, 2003). BAFF can bind 3 TNF-α 
receptors i-e BAFF-R, B cell maturation antigen (BCMA) and transmembrane activator and 
cyclophilin ligand interactor (TACI).The mechanism by which BAFF regulates B cell 
survival is not known but in vitro studies have shown increased B cell proliferation and 
BAFF-KO mice studies have shown defect in progression of B cells (Craxton et al, 2005; 
Henley et al, 2008). 
In human, increased BAFF level has been demonstrated in autoimmune diseases such 
as rheumatoid arthritis, Sjögren’s disease, SLE and multiple sclerosis (Cheema et al, 2001; 
Zhang et al, 2001; Henley et al, 2008) 
 
IL-2 
IL-2 cytokine is secreted by activated T cells and has involvement in B cells 
differentiations which express IL-2Rα on their surface. IL-2 is also involved to increase CD23 
expression on normal B cells which is mainly expressed on pre-switched memory B cells and 
is lost after class switching (Hivroz et al, 1989). 
 
IL-4 
IL-4 is produced mainly by T helper cells with pleiotropic effects on B and T 
lymphocytes.IL-4 acts as growth factor and induces high levels IgE and IgG4 production in 
human while IgG1 and IgE production in mice.IL-4 is also shown to induce expression of 
CD23 molecule which is low affinity receptor for IgE (Lundgren et al, 1989) 
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IL-6 
IL-6 is a pleiotropic cytokine which acts as stimulator for B and T cells and promotes 
B cell proliferation and final maturation into Ig secreting plasma cells. IL-6 is produced by T 
cells, macrophages and endothelial cells. IL-6 is also inflammatory cascade player and been 
involved in different autoimmune diseases like RA. IL-6 produces acute phase protein 
production and fever (Lipsky, 2006). 
 
Along with these cytokines IL-10 and IL-21 are also involved in B cell regulatory 
machinery by helping B cell survival, proliferation and differentiation. IL-10 and IL-21 are 
produced mainly by T cells but IL10 is also produced by NK cells, B cells and monocytes 
(Janeway et al, 2005) 
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1.7 Functions of B cells 
 
B cells are important components of a normal immune responses and play a key role 
in maintaining cellular and humoral protective memory. In healthy individuals, B cells have 
also other essential functions in regulating immune responses than just being precursors of 
antibodies. They act in variety of ways directly and indirectly in regulation of other players in 
immune response (Figure 1.7). For example, lymphotoxin α/β expressed by B cells is 
responsible for differentiation of follicular dendritic cells. Activated B cells secrete 
costimulatory molecules which are essential for effector T cells and produce cytokines 
influence the functions of antigen-presenting dendritic cells. They are also involved in 
activation, anergy, differentiation and expansion of T cells. Antigen-presenting M cells can 
not develop in gastrointestinal mucosa in the absence of B cells (Lipsky, 2001). Additionally, 
they play important role in orchestration of inflammatory cascade by producing 
proinflammatory cytokines, such as tumour necrosis factor-α (TNF-α) and interleukin 6 (IL-6) 
and most importantly, they link innate, inborn and acquired adaptive immunity by using 
specific receptors expressed on B cells (Dörner, 2006).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 Different functions of B cells in immune system: The various functions of B cells. APC: antigen-
presenting cell; FDC: follicular dendritic cell (adopted from Dörner, 2006) 
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1.8 Human memory B cells and marginal zone B (MZB) cells 
 
The basic principle of acquired immunity for disease control depends on phenomenon 
of immunological memory. This memory is maintained by memory B cells, plasma cells and 
memory T cells. Different subpopulations of memory B cells have been described in section 
1.5 depending on phenotypic presence of CD27+ surface expression and somatic mutations in 
their immunoglobulin receptor comprising large circulating B cells in periphery. In secondary 
immune responses the memory B cells respond to lower doses of antigens facilitating quick 
update and presentation. These memory cells include pre and post switched memory cells 
depending on IgD surface expression (Figure 1.8). The majority of naïve B cells after 
encountering antigen under proliferation, somatic hypermutation and class switching with 
help of T cells in germinal centres of secondary lymphoid organs. However there is fraction 
of IgM+ memory B cells which are assumed to mature in T cell independent way, particularly 
the marginal zone of spleen (Klein et al, 1998, Takizawa et al, 2006). 
Splenic marginal zone is a unique B cell compartment which contains B cells having 
high surface expression of IgM and complement receptor 2(CD21) which exhibit rapid 
activation and Ig secretion in response to blood borne T independent (TI) antigens. These 
SMZ B cells are shown to carry somatic mutations. Mutated antibodies can be raised after 
immunization with T-independent polysaccharide vaccines. IgD+(IgM+CD27+IgD+) memory 
B cells have gained specific interest in research in recent years due to their presence in 
peripheral blood (Weller et al, 2004).These memory B cells do not shift to class-switch 
memory by various stimuli invitro (Shi et al, 2003) and accumulating lines of evidences have 
suggested that these IgD+ memory B cells play important role in humoral immunity and in 
some diseases. 
It is still debated that when and where these IgD+ memory B cells develop. These cells 
are suggested to be generated in spleen and control streptococcus pneumococcal infections 
because of their reduction in patients with inflammatory bowel disease patients related to 
impairment of splenic functions (Sabatino et al, 2005). These cells are completely absent in 
asplenic and splenectoy patients with an impaired immune responses to encapsulated bacteria. 
These studies also suggested that physiological and transient predisposition to pneumococcal 
infections of young children (0-2 years) is associated with lack of these IgD+ memory B cells 
in spleen and of serum polysaccharide IgM (Kruetzmann et al,2003).All these findings 
induced research interest in IgD+ memory B  cells. 
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Figure 1.8 Origin and function of mature and IgD+ memory B cells. IgM memory B cells might be able to 
migrate to sites of inflammation and recognize invading pathogens through the B cell receptor (BCR) and 
possibly other pathogen-binding co-receptors. Switched memory B cells are generated from bone marrow–
derived mature B cells after somatic mutation and class switch in the germinal centers (adopted from 
Kruetzmann et al, 2003). 
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2. Autoimmunity 
 
During lymphocyte production and maturation, they are schooled for tolerance to self 
antigen and cells who react to self antigen undergo programmed cell death, apoptosis but 
despite this strict regulatory system, immune system could be broken and leads to 
inflammatory reaction against own body tissues and ultimately develop autoimmune diseases 
which include large variety of diseases and few among them are rheumatoid arthritis, SLE and 
Sjögren’s disease. Distinguishing self from non self is fundamental to normal immune 
response. Failure of deleting particular autoreactive clone can leads to emerge autoreactive 
condition. 
Despite extensive research in this field it is still to be determined how and when this 
self tolerance becomes impaired and pathogenic causing autoimmune diseases. 
 
 
2.1 Rheumatoid arthritis 
 
Rheumatoid arthritis (RA) is a complex immune-mediated inflammatory disease that 
particularly affects the small diarthodial joints of hands and feet. Chronic inflammation leads 
to progressive cartilage degradation and bone erosion which causes pain, joint deformity, and 
functional disability (Firestein, 2003; Siegel, 2008). RA is common chronic polyarthritis with 
prevalence 0.5-1.0 % (Alamanos et al, 2005). Two third of patients are women and the 
incidence of RA peaks at about 60 years of age. RA was first considered an autoimmune 
disease based on the identification of rheumatoid factor (RF) in the sera of patients and 
characterization of these factors as auto antibodies (Franklin et al, 1957). Further research 
proposed that RA represents a localized immune complex disease characterized by production 
of RF in synovium, the formation of RF-immune complex that fix complements with ensuing 
consumption of complements within the joint and recruitment of variety of cells like T cells, 
B cells and macrophages that become activated and contribute to inflammation and joint 
damage (Zvaifler ,1973). Diagnosis of patients with rheumatoid arthritis is based on these 
inflammatory hallmarks and in addition certain criteria based on clinical and laboratory 
findings should be fulfilled to classify various stages of rheumatoid arthritis. One of RA 
disease measurement is based on DAS (disease activity score using 28joint counts) score 
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based on swollen and tender joints count used by clinician in regular practice and clinical 
trials for response evaluation (www.das-score.nl). 
 
Below is American college of rheumatology (formerly American rheumatism association) 
criteria for classification of RA which was established in 1987. 
 
1. morning stiffness > 1hour before maximal improvement 
2. arthritis of three or more joint areas 
3. swelling of hand joints 
4. symmetric swelling (arthritis) 
5. rheumatoid nodules 
6. serum rheumatic factor 
7. radiological changes 
Criteria 1 through 4 must have been presented for at least 6weeks (Arnett et al, 1987) which 
was further revised in 1991 by American college of rheumatology in four main classes 
(Hochberg et al, 1992) depending on patient activities. 
Class1=able to perform usual activities, but limited in vocational activities 
Class2=able to perform usual self-care and vocational activities 
Class3=able to perform usual self care but limited vocational activities 
Class4=limited in ability to perform self care, vocational and avocational activities. 
A chronic rheumatic disease often leads to irreversible joint destruction causing permanent 
loss of bone architecture. 
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2.2 Pathophysiology of RA 
 
The etiology of rheumatoid arthritis remains unknown but insights into pathogenic 
pathways have been accumulated from previous two decades indicate role of main immune 
system player cells including monocytes, neutrophils, macrophages, endothelial cells, 
fibroblasts, T cells and B cells participate in inflammatory process. In RA, CD4+ T cells, B 
cells and macrophages cause bone marrow infiltration by acting in variety of ways (Figure 
2.1).Macrophage and fibroblast-like synoviocytes markedly increase bone hyperplasia. 
Locally expressed matrix metalloproteinase, serine proteinases and aggrecanases digest 
extracellular matrix and destroy articular structure (Firestein, 2003) 
Antigen associated with RA are probably presented by APCs to T cells to entail binding of 
antigenic peptides to class II MHC molecules and more than 80% patients of RA carry so 
called shared epitope of the HLA-DRB1*04 cluster (Gregersen et al, 1987).These disease 
associated HLA-DR alleles are believed to present arthritis –related peptides which cause 
stimulation and expansion of autoantigen-specific T cells in joints or lymph nodes or both 
(Smolen et al, 2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 Cells involved in the immunopathogenesis of RA. Endothelial cells assume the phenotype of "high 
endothelial venules". Recirculating CD4+ T cells migrate into the synovium and play a crucial role in initiating 
the autoimmune response. Activated cells secrete cytokines and mediators which cause signs and symptoms of 
disease and contribute to the inflammatory self-perpetuating processes (Adopted from Afeltra, 2001) 
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2.2.1 Role of B cells in pathophysiology of RA 
 
The role of B cells in RA is now well established from previous research, suggesting B 
cells to contribute the disease in variety of ways. B cells are involved in autoantibody 
production and autoantigen processing and help in the inflammatory cascade by producing 
different cytokines (interleukin 1,6 and 10, TNF-α and lymphotoxin α/β) and chemokines 
among which TNF and IL1 enhance production of IL-6 and IL-10 which stimulate B cell 
function via a feedback loop therefore exacerbate chronic inflammation . Activated B cells 
express co-stimulatory molecules such as CD154 and contribute in evaluation of T effector 
cells and also support activating autoreactive T cells by expressing costimulatory such as 
CD80/CD86 and CD40 molecule. As shown in Figure 2.2, the overall activity of B cells is 
observed to be enhanced in RA and they are found in synovium where they form complexes 
with T cells and develop tertiary lymphoid tissue structures (Kim et al, 2000).B cells also take 
part in antigen driven specific immune responses in ectopic lymphoid tissues and 
differentiating into plasma cells. There is evidence that chronic autoimmune disease causes 
changes in the repertoire of specific antigen receptors. Disturbance in B cell receptor editing 
and central or peripheral tolerance machinery additionally contribute to abnormal B-cell 
activation and proliferation (Hansen et al, 2007; Dörner, 2006; Tsoko et al, 2004).  
 
 
 
 
 
 
 
 
 
Figure 2.2 Potential roles of B cells in the immunopathgensis of RA: Different mechanistic approach by B 
cells in cartilage loss (adopted from Dörner, 2006) 
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2.3 Therapeutic Targets in RA 
 
Therapy to autoimmune diseases is a challenging task and none of the available drugs 
for rheumatoid arthritis can not cure the disease but only offer means to control flares and 
suppress symptoms and help to prevent disease at certain extent. Unfortunately, short or 
longterm intake of these medications exerts some adverse effects. The drugs selection and 
efficacy depend on personal responses and severity of disease manifestations. Traditionally, 
rheumatoid arthritis has been treated with anti-inflammatory non-steroidal drugs, 
glucocorticoids and disease-modifying antirheumatic drugs. Therapeutic options for 
rheumatoid arthritis have tremendous increase in past decade with the introduction of 
biological agents. A large variety for cellular and cytokine targets have been identified with 
specific inhibitors being approved to treat (Bingham, 2008). 
To cope with mild RA, among routinely used drugs include glucocorticoids and 
disease modifying antirheumatic drugs. Glucocorticoids drugs include prednisolone, 
dexamethasone and hydrocortisone. Glucocorticoid is powerful drug with capability to 
suppress both inflammatory and immune responses and help in halting destructive disease 
processes (Weinblatt, 2003; Vallerskog, 2007).Unwanted effects of these drugs could include 
osteoporosis, suppression of immune reactions against infections and iatrogenic Cushing’s 
syndrome. 
 
Disease modifying antirheumatic drugs (DMARD) 
The most commonly used small molecule disease modifying antirheumatic drug is 
methotrexate which is believed to be a cornerstone of most treatment regimes in rheumatoid 
arthritis with highest retentions rate as compared with other agents (Weinblatt, 1995). 
Methotrexate is a folate antagonist being a metabolite disturbing the DNA synthesis and cell 
division. 
Alternative drugs are azathioprine and cyclophosphamide. All these drugs effect 
cellular proliferation, so unwanted effects could be usual outcome in shapes of anaemia, and 
decreased immune responses. So longterm and devoted research in the field of drug 
development offered different biological agents which proved to be very efficient in 
autoimmune diseases.  
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2.3.1 Biologics in RA 
 
Now a days a large variety of biological agents are available in treatment of RA and 
many are still under clinical trials and yet to be approved for treatment. 
 
 
1) Anti TNF-α therapy 
 
As TNF is involved in enhancing inflammation it was chosen as targeting therapy to 
block and ultimately reduce TNF in blood. Three TNF antagonists are currently approved for 
treating RA; 1) Adalimumab (ADA), a fully human monoclonal antibody against TNF-α. 2) 
Etanercept (ETN) the TNF receptor (p75): FcIgG construct.3) Infliximab (IFX), a chimeric 
monoclonal antibody. Major difference in these available compounds is their methods of 
delivery and frequency of administration. Two newly introduced compounds which also 
inhibit TNF are in late stages of clinical development, Certolizumab (CZP) and Golimumab 
(GLM). Certolizumab pegol is construct of ‘Fab’ of humanized monoclonal anti-TNF 
antibody bound with polyethylene glycol (PEG)  that do not interfere with TNF binding 
properties while Golimumab is fully human monoclonal antibody to TNF(Bingham,2008). 
Most of these drugs have been shown to be effective in combination with disease 
modifying drugs like methotrexate (Smolen et al, 2003; Smolen et al, 2007). 
 
2) IL-6 receptor inhibition 
 
An alternative target for treatment of RA is use of cytokine receptor inhibitions which 
are involved in inflammatory cascade. So different cytokines including IL-6, IL-1, IL-15 and 
RANKL have been chosen as suitable therapeutic targets. Tocilizumab is a humanised anti 
IL-6 R monoclonal antibody which binds with soluble and membrane-expressed IL-6 R 
preventing IL-6 mediated proinflammatory activity (Emery et al, 2008,Genovese et al,2008). 
Tocilizumab has been approved in February 2009 for the treatment of active RA inadequately 
treated with at least methotrexate.  
 Pleiotropic cytokine IL-6 blockade is shown to be beneficial in rheumatic diseases. 
IL-6 is not only stimulator of B and T cells functions but also promotes maturation of 
plasmablasts during their final maturation stage as well as  triggering immune system in 
playing pathogenic role development of inflammatory manifestation in RA(Lipsky,2006). 
Longterm impact of anti-CD20 mediated transient B cell depletion on memory B cells in patients with RA 
 
24 
 
 
3) CTLA-4 Ig molecule 
 
CTLA-4 is a molecule that can out-compete CD28 for ligation of the B7 molecule. Its 
affinity for the B7 is 10-20 times greater than that of CD28. Inhibition of CD28 mediated co-
stimulation signals is a potent means of immunosuppression that can be achieved by blocking 
either CD28 or CD80 and CD86. So biologically these differences in affinity result in 
limitation and subsequently down regulation in T cell responses. Abatacept (CTLA-4 Ig) is 
the first in a new class of drugs targeted at T-cell function in autoimmune disease: the co-
stimulation blockers. In Clinical trials, Abatacept has favorable effects in patients with 
psoriasis vulgaris and in patients with RA. This drug was also being used for avoiding graft 
rejection after organ transplantation. It has shown safety and efficacy in rheumatoid arthritis 
and in December 2005 FDA approved Abatacept for treatment of rheumatoid arthritis (Acuto 
et al, 2003; Malmström et al, 2005). 
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2.4 B cell targeted therapies in RA 
 
1) Anti CD20 molecule 
CD20 molecule is a B cell surface marker expressed on major B cells populations 
from pre-B cell stage to memory B cells except pro-B cells and plasma cells. CD20 is 33-
37kd membrane associated phosphoprotein which functions as a calcium channel subunit. 
Due to this property of CD20 molecule, it affects B cell activation; differentiation and cell 
cycle progression from G1 to S phase (Silverman et al, 2003). 
Rituximab is a chimeric anti CD20 monoclonal antibody and have been effective in 
treating patients with RA and other autoimmune diseases (Keystone, 2005). Rituximab has 
shown promising clinical results and suitable treatment for RA patients refractory to therapy 
with tumour necrosis factor blockers (Leandro et al, 2002; Edwards et al, 2004) 
 
 
2) Anti CD22 molecule 
CD22 is a membrane protein expressed on B cell surface during maturation stages of 
differentiation and appears to upregulate the B-cell receptor and serves as an adhesion 
molecule. CD22 deficient mice study suggests its key role in B cell development and survival. 
Epratuzumab is a humanized antiCD22 monoclonal antibody. The results from open label 
study showed that Epratuzumab may be effective and safe in patients with moderately active 
SLE (Dörner et al, 2006). Currently Epratuzumab is under clinical trials for studies in SLE, 
NHL, lymphoma, B cell NHL and leukemia (Hawker, 2008) 
 
3) Anti BAFF 
BAFF (also known as BlyS) is critically involved in B cell maturation and 
development. Several lines of evidence implicate BAFF signalling in autoimmunity because 
autoantigen binding B cells may have increased dependency on it and circulating level of 
increased soluble BAFF are increased in autoimmune diseases such as rheumatoid arthritis 
(Cheema et al,2001), SLE (Zhang et al,2001) and Sjögren’s disease (Mariette et al,2003). So 
inhibition of BAFF signalling is therapeutic option in B cell medicated diseases. Belimumab 
is anti-BAFF monoclonal antibody and during clinical trials have shown biological activity in 
humans including moderate decrease in peripheral blood B cells (Vugmeyster et al, 2005; 
Wei et al, 2007) 
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2.5 Transient B cell depletion by anti-CD20 antibody Rituximab 
 
 Rituximab is a chimeric monoclonal antibody which is a construct of human IgG1 and 
Kappa constant regions and of mouse variable regions from a hybridoma directed at human 
CD20. Rituximab was developed to treat non-Hodgkin lymphomas but was also approved for 
treatment of rheumatoid arthritis in 2006. It selectively depletes CD20+B cells from peripheral 
blood, secondary lymphoid organs and bone marrow. Only pro-B cells and plasma cells are 
spared as they do not express CD20 molecule (Rouziere et al, 2005; Silverman, 2003; 
Silverman et al, 2007) 
  Rituximab follows four possible mechanisms to deplete B cells from RA patients 
which are summarized in Figure 2.3. 
1) Antibody dependent cellular cytotoxicity 
Anti CD20 antibody may permit antibody dependent cell mediated cytotoxicity which occurs 
after recognition of Fc portion of the antibody by appropriate receptors on cytotoxic cells. 
2) Complement dependent cytotoxicity 
It occurs after binding of antibody to extracellular domain of CD20 antigen resulting 
complement activation and lyse the targeted cell. 
3) Altering B cells response 
Another possible way is to alter the ability of B cells to respond to antigen or other stimuli. 
4) Apoptosis 
Anti CD20 may initiate programmed cell death by shifting CD20 into a lipid-raft environment 
thereby altering calcium flux and inducing apoptotic events. 
Fc receptor mediate cytotoxicity is prominent in B cell destruction in peripheral blood 
whereas complement activation kills B cells in lymphoid organs (Tsokos, 2004; Browning, 
2006) 
Rituximab has been investigated intensively in wide range of autoimmune diseases 
including rheumatoid arthritis, SLE, Sjögren’s disease, idiopathic thrombocytopenia, IgM-
mediated polyneuropathy, Factor VIII deficiency, inflammatory myositis and ANCA 
associated vasculitis (Cohen, 2005; Edwards et al, 2006; Browning, 2006; Martin et al, 2006; 
Keogh et al, 2006) 
Rituximab results in selective loss of virtually all CD20+ B cells in the periphery and 
in the majority of patients this level remains greatly depressed with very few detectable 
CD19+ cells for 4-5 months after single dose of rituximab. The extent of depletion is variable 
in different B cell subsets. Regeneration data have revealed that the peripheral B cell 
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repopulate with newly emerging populations leading to a new naïve B cell pool (Leandro et 
al, 2002; Keystone, 2005; Roll et al, 2006). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3 Mechanism of action of anti-CD20 antibodies: B cells coated with anti-CD20 molecule are killed 
by different mechanisms (adopted from Browning, 2006) 
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Objectives of Project 
 
The efficacy of therapeutic B cell depletion using rituximab has gained specific 
interest in understanding the role of B cells in autoimmune diseases like RA. Autoimmunity is 
characterized by significant changes in the lymphoid system. Regarding the B cell system 
there is evidence for a shift in the expressed B cell repertoire of specific B cell receptors. 
Disturbance in B cell receptor editing and central or peripheral tolerance contribute to 
abnormal B cell activation in chronic immune mediated diseases (Leandro et al, 2006; 
Silverman, 2006). Therefore resetting the immune system by transient B cell depletion seems 
to be an interesting goal. Rituximab, a B cell depleting anti-CD20 antibody has shown 
profound efficacy and promising results in recent years. Rituximab holds good safety record 
in all studies except for mild infusion reactions. 
Intravenous application of 2x1g anti-CD20 antibodies (Rituximab) results in selective 
loss of vast majority (>97%) of B cells expressing CD20 molecule from peripheral blood and 
secondary lymphoid organs. B cell numbers in blood remain low for about 6-12 months 
(Anolik et al, 2004). Clinical efficacy of rituximab in treating RA patients has been well 
documented in clinical trials (Edwards et al, 2004; Cohen et al, 2006; Emery et al, 2006). As 
plasma cells being CD20 negative are not depleted during rituximab therapy therefore serum 
immunoglobulin levels derived from long lived plasma cells are maintained (Browning, 
2006). Disease activity score and RF levels have been reported to be reduced in an open label 
study with RA patients (Kneitz et al, 2004). In another study increased BAFF level after 
rituximab therapy have been observed(Vallerskog et al, 2006) along with other serological 
changes including reduction in IgA-RF, IgG-RF and anti-CCP antibodies have been 
documented(Cambridge et al,2003;2006). 
During regeneration phase, B cells showed a characteristic pattern in peripheral blood 
with elevated numbers of immature B cells which differentiate into mature/naïve B cells and 
dominate during later time points (Leandro et al, 2006; Roll et al, 2006). Repopulation data 
have revealed a delayed recovery of memory B cells after rituximab, particularly of pre-
switched (IgD+CD27+) memory B cells studied over a period of two years (Roll et al,2006). 
Memory B cells seem to be particularly important targets for treatment since disease driving 
cells seem to be part of this populations. Regeneration of pre-switched memory B cells could 
be correlated with response and non response to rituximab therapy in RA (Roll et al, 2008). In 
this study good responders were shown to have diminished recovery of IgD+ memory B cells 
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as compaired to non responders who recoverd these cells more numerously. In addition, 
patients with lower number of memory B cells prior to treatment had significantly more 
durable response to rituximab. 
Memory B cells are also associated with additional disease conditions. An overall 
memory B cell deficiency is observed in patients with graft-versus-host disease after 
allogeneic hemopoietic stem cell transplantation where distribution of B, T and natural killer 
cell numbers is normal (Greinix et al,2008). Similar findings were observed in patients with 
common variable immunodeficiency (Agematsu et al, 2002). A skewed distribution of 
peripheral memory B cells is also observed in patients with Sjögren’s disease (Hansen et al, 
2002) and SLE (Odendahl et al, 2000). These observations formed the basis of studying 
memory B cells after B cell depletion therapy in this thesis. 
A precise role of memory B cells in autoimmunity still remains unclear. Since, IgD+ 
memory cells are particularly susceptible to rituximab therapy and their extent of repletion is 
connected to clinical efficacy in treated patients, we undertook a detailed molecular analysis 
and comparison of memory B cells and particularly IgD+ memory B cells on the single cell 
level in patients who underwent rituximab mediated B cell depletion. We prospectively 
analyzed Ig-VH3 gene rearrangement of B cell subsets with regard to their mutational pattern 
and frequency before B cell depletion and during repletion phase over a period of six years. 
The mutational pattern of memory B cell subsets was also compared with patients who 
underwent allogeneic and autologous stem cell transplantation (SCT). In addition to the study 
of variable genes, Ig receptors of class switched memory B cells were analyzed for expression 
of IgG and IgA during rituximab mediated B cell depletion therapy. 
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Aims of study 
The goal of the thesis was to study the longterm effect of Rituximab on the memory B cell 
pool. We addressed mainly the following questions 
 
 Regeneration pattern of memory B cells after rituximab therapy. 
 
 Acquisition of B cell receptor (IgR) mutations in IgD+ memory B cells after 
rituximab mediated B cell depletion 
 
 Development of mutationally class-switched Ig Receptors during regeneration  
 
 
 Detection of IgG and IgA specific CD27+ memory B cells before and after anti-
CD20 antibody treatment  
 
 Acquisition of IgR mutations in memory B cells after Allogeneic and autologous 
stem cell transplantation. 
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3. Patients, Materials and Methods 
 
3.1 Patients 
18 Patients with a median age 52years (31-67years) diagnosed with active rheumatoid 
arthritis were included in study of monoclonal anti-CD20 antibody (rituximab) treatment. The 
patients were refractory to previous treatment with Disease Modifying Anti-Rheumatic Drugs 
(DMARD) including methotrexate and /or TNF-α-antagonists. All Patients met the ACR 
(American College of Rheumatology) revised criteria for RA diagnosis. They were on stable 
doses of methotrexate before treatment with 1000 mg rituximab (Mabthera ®, Hoffmann La – 
Roche, Grenzach – Whylen, Germany) twice, two weeks apart. They stayed on standard 
methotrexate therapy during the whole study. 
Informed consent was obtained from patients and normal donors according to the 
protocol approved by ethical committee of University of Würzburg, Germany. 16 patients 
were studied for pre-switched memory (CD19+CD27+IgD+) B cells at single cell level and 
amplified Ig-VH3 family gene rearrangements by using single sorting technique followed by 
nested RT-PCR approach. Patients were studied at baseline prior to initiation of rituximab in 7 
patients and categorically during 6 years post-treatment B cell repletion phase in 9 patients 
Three patients were studied prospectively before and one year after RTX. For disease control, 
one patient with SLE after RTX treatment, 2 patients one year after autologous stem cell 
transplantation and 3 patients 1 year after allogeneic stem cell transplantation (ASCT) were 
studied for comparison. Among allogeneic SCT patients, two patients were suffered from 
acute myeloid leukemia and one with myelodysplastic syndrome. Conditioning regimen 
included TBI (12 Gy) with cyclophosphamide (60 mg/kg x 2) in 2 patients or fludarabin (30 
mg/ m2) and melphalan (75 mg/m2)  in 1 patient. GvHD prophylaxis was done with 
cyclosporine A and mycophenolate mofetil. As control, 4 healthy donors were analyzed. On 
the otherhand, 2 RA patients and 2 ASCT patients were studied for class-switched memory 
(CD19+CD27+IgD-) B cells prior and 1 year post-treatment period. 
To observe rituximab mediated changes in Isotype switching, Post-switched memory B cells 
were studied in 2 patients before and 1 year after rituximab therapy to make Isotype (IgG and 
IgA production) analysis during treatment. 
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3.2 Peripheral blood mononuclear cells (PBMCs) preparation 
 
Peripheral blood mononuclear cells were prepared from peripheral blood (60ml) by 
ficoll-paque plus separation (GE Healthcare, Munich, Germany). 
Equal volumes (10ml) of blood were diluted with isotonic solution (NaCl) and were 
laid over 20ml of Ficol followed by centrifugation at 900g for 25min without brake. As a 
result, differential layers are formed based on cellular density having red blood cells at the 
bottom and whitish ring like layer rich in PBMCs between fluids which is separated and 
washed twice with RPMI 1640 medium containing penicillin-streptomycin and L-glutamine 
with centrifugation speed 1300g for 10min.PBMCs were counted microscopically stained 
with trypan blue on a Neubar chamber. Finally PBMCs were suspended in PBS+0.5% BSA 
buffer and put on ice till further use. 
 
3.3 Flow cytometry 
Before single cell sorting, Immunoflourescence labelling for flow cytometry was 
performed for differentiating different memory B cell subpopulations by incubating PBMCs 
with a variety of Immunoflourescence labelled antibodies. These were APC-labelled anti-
CD19, FITC-labelled anti-IgD, APC labelled anti-CD23, PE-labelled anti-CD27, APC 
labelled anti-CD21 and PerCP-labelled anti-IgM (Becton Dickinson, San Jose, CA., USA). 
Cell incubation with antibodies was performed at 4°C for 15 minutes in PBS/0.5%BSA 
followed by subsequent washing. Data acquisition and flow cytometric analysis was 
performed by FACSCalibur flow cytometer using Cell Quest software (Beckton Dickinson, 
San Jose, CA). 
 
3.4 Cellular preparation for single cell sorting 
Memory B cell subpopulations are easily distinguishable between pre and post 
switched memory B cells on the basis of IgD surface expression. So for single B cell sorting 
we stained our cells as described in  above section  by using RNAase free sterile tubes and 
following 3 fluorescence colours were used: APC labelled CD19, PE labelled CD27 and FITC 
labelled IgD. Finally cells were filtered by using MACS filter columns and put on ice until 
sorted. 
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3.5 Single Cell sorting 
 
3.5.1 Lower reaction mix 
A lower reaction mix which is cocktail of different ingredients(shown in table below) 
is prepared and put into 96 well plate which would be used for sorting. Low reaction mix is a 
lysis buffer. 
Titan One Tube RT-PCR kit and Oligo dT15 was purchased from Roche, RNAsin 
from Promega while BSA and Triton were purchased from Sigma Aldrich. 
 
To each of 96 well, 30µl is added and plate is put on ice until sorting proceeds.  
 
 
Lower reaction mix: Volume/well 30 µl 
 
 
 
 
 
 
 
 
 
                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
Reagents Volume µl 
(100 tests)                                   
Final conc. /well 
• Triton X (10%)  
 
• Oligo DT(800 ng/ul) 
 
• BSA(10ug/ul) 
 
• RNAsin(40U/ul) 
 
• DTT(100mM) 
 
• RNAse free H20  
 
2145µl  
 
500 µl 
 
50 µl 
 
5 µl 
 
50 µl 
 
250 µl 
 
5mM 
 
20U 
 
1% 
 
400ng 
 
0.5ug 
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3.5.2 Sorting 
Individual B cell sorting was carried out in a FACSDiVa (Beckton Dickinson, San 
Jose, CA) cell sorter which was outfitted with an automated cell deposition unit which 
provides 99.9% population purity. Pre and post switched memory B cells were sorted 
individually into each of 96 well plate. After sorting plate was spun for a very short time and 
cell were lysed in lysis buffer. During lysis action the B cell is lysed and mRNA comes out of 
cell. 
 
3.5.3 Upper reaction mix 
Upper reaction mix, which is a combination of RT-PCR buffer, dNTPs and reverse 
transcriptase enzyme in water, added to the sorted B cells. The composition of upper reaction 
mix is shown in table below. 
Reverse transcriptase and RT-PCR buffer was provided in Titan One Tube RT-PCR kit and 
dNTPs were purchased from PeqLab. 
 
 
Upper reaction mix: Volume/well 20 µl 
 
 
 
 
 
 
 
 
 
 
3.5.4 cDNA synthesis 
The plate was incubated at 50ºC for 1 hour and cDNA is prepared in this stage from 
mRNA by reverse transcriptase reaction. Plate was stored at 4ºC for further use and could be 
frozen at -20ºC for 3-4 years stability. 
 
Reagents Volume µl 
(100 tests)                                   
Final conc. /well 
• H20 
 
• RT-PCR buffer 
 
(5x contains Mg) 
 
• Reverse transcriptase 
(20U/µl) 
 
• dNTPs(10mM) 
 
800 µl 
 
1000 µl 
 
 
 
100 µl 
 
 
100 µl 
 
 
 
1x 
 
 
 
20U 
 
 
0.2mM 
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3.6 Amplification of Ig-VH3 by nested PCR 
 
Nested RT-PCR approach was employed for the amplification of VDJ rearrangements 
of Ig-VH3 gene from cDNA plates after single sorting. Primer details of Ig-VH3 family were 
followed as described previously (Brezinschek et al, 1995; Ruzickova et al, 2002).The V and 
J specific primers were synthesized by MWG Biotech AG. 
 
Primer sequences are detailed below. All primers are from ‘5’ to ‘3’. 
 
 
3.6.1 Oligonucleotide Sequences 
 
Heavy Chains-VHDJH rearrangements 
3.6.2 External Primers 
VH3 E– CCATGGAGTTTGGGCTGAGC 
JH1, 2, 4, 5 E – TGA GGA GAC GGT GAC CAG GGT 
JH3 E – TAC CTG AAG AGA CGG TGA CC 
JH6 E – ACC TGA GGA GAC GGT GAC C 
 
3.6.3 Internal Primers 
VH3 N–  GAGGTKCAGCTGGTGGAGTCTGGGGG 
JH1, 3, 4, 5 N – CGA CGG TGA CCA GGG TBC CYT GGC C 
JH2 N – CGA CAG TGA CCA GGG TGC CAC GGC C 
JH6 N – CGA CGG TGA CCG TGG TCC CTT GCC 
 
IUB codes used in primers correspond to following mixes K=GT, Y=CT, B=GTC 
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3.7 PCR amplification rounds 
 
PCR amplification was performed on geneAmp PCR system 9700(Perkin Elmer) 
 
 
3.7.1 External amplification round 
External primers were used to Amplify VDJ rearrangement from cDNA which was 
performed by making master PCR mix with following ingredients: 
Primers concentration was 100 pmol/µl 
 
Lower Reaction mix Volume/well 25 µl        
Reagents         volumes 
dH2O          1428µl 
MgCl2          800 µl 
dNTPs          160 µl 
VH3 (E)         56 µl 
JH mix E (1,2, 3, 4, 5,6)       56 µl 
(JH mix =40 µl JH1, 2,4,5E  +10 µl JH3E + 10 µl JH6E) 
 
Upper Reaction mix Volume/well 50 µl 
Reagents         volumes 
dH2O          4150 µl 
10x buffer II         800 µl 
TAQ polymerase        50 µl 
5 µl cDNA template was adding to each of 96 well plate. 
The AmpliTaq polymerase, 10X buffer II and MgCl2 were purchased from Applied 
Biosystems. 
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External PCR Run 
 
The amplification temperatures and cycles were as following: 
 
 
1cycle 
 
Followed by  
 
35cycles 
 
 
Followed by a final extension at 72ºC for 5min and stored at 4ºC to process for internal 
amplification round. 
 
 
3.7.2 Internal amplification round 
 
Internal/Nested PCR Run 
The nested PCR was performed in identical manner as in external amplification round 
except following changes. 
• Nested primers were used as described in section 3.6.3. 
• The template used was 5ul of external PCR product. 
• Annealing temperature was 65ºC used to yield highly specific Ig-VH3 products. 
• Numbers of cycles were reduced to 30. 
Amplified DNA of Ig-VH3 family was stored at 4ºC until further use as described in section 
3.10. 
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3.8 Primers used in Isotype studies 
 
Nested PCR approach was also employed for amplification of IgG, IgA and IgM 
producing specific B cells by using Isotype α/µ/g specific primers. Beauty of this technique is 
to amplify all Ig-VH families from VH1-VH6 by combining all family specific primers in same 
PCR amplification instead of amplifying all families separately. We mainly used this 
technique to categorically separate IgG and IgA producing B cells in Post-switched memory 
B cell compartment during rituximab therapy. 
Set of Ig-VH primers used in external and internal PCR rounds are described below. 
All primers were synthesized by Metabion AG. 
 
3.8.1 External Primers 
 
 
Following external primers were used: 
VH1 LC: CCA TGG ACT GGA CCT GGA 
VH4 LC: ATG AAA CAC CTG TGG TTC TT 
VH6 LC: ATG TCT GTC TCC TTC CTC AT 
VH2 LC: ATG GAC ACA CTT TGCTMC AC 
VH3 LC: CC ATG GAG TTT GGG CTG AGC 
VH5 LC : ATG GGG TCA ACC GCC ATC CT 
Ecµ: TCA GGA CTG ATG GGA AGC CC 
Ecg : CAG GCC GCT GGT CAG AGC G 
Eca: GGA AGA AGC CCT GGA CCA GGC 
Isotype specific primers were used separately in combination with all VH primers. 
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3.8.2 Internal Primers 
Detailed sequences of all primers used are described below. 
VH3 FM: GAG GTG CAG CTG GTG GAG TCT GG 
VH4 FM: CAG GTG CAG CTG CAG GAG TCG GG 
VH6 FM: CAG GTA CAG CTG CAG CAG TCA GG 
JH Mco: CTT GGT GGA RGC TGA RGA GAC GGT GAC C 
VH1 FM: GAG GTG CAG CTG GTG CAG TCT GG 
VH5 FM: ACC AGG CAG GCG ATG ACC AC 
VH2 FM: CAG GTC ACC TTG AAG GAG TCT GG 
EcaN: ACC AGG CAG GCG ATG ACC AC 
VH internal primers in combination with JHMco were used in internal PCR amplification 
except in case of IgA internal PCR α internal primer was used instead of JHMco. 
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 3.9 PCR amplification rounds in Isotype studies 
Nested PCR amplification rounds were carried out in similar way as in Ig-VH3 
amplification with some difference described below. 
 
3.9.1 External PCR run 
External PCR run was carried out by using following master mix. 
Primers concentration was 100 pmol/µl 
 
Lower Reaction mix Volume/well 25 µl 
Reagents         volumes 
dH2O          1148µl 
MgCl2          800 µl 
dNTPs (10mM)        160 µl 
Ecµ/Ecα/Ecg         56 µl 
VH1LC         56 µl 
VH2 LC         56 µl 
VH3 LC         56 µl 
VH4 LC         56 µl 
VH5 LC         56 µl 
VH6 LC         56 µl 
Upper Reaction mix Volume/well 50 µl 
Reagents         volumes 
dH2O          4150 µl 
10x buffer II         800 µl 
TAQ polymerase        50 µl 
5 µl cDNA template was used in external PCR run. 
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The amplification temperatures and cycles were as following: 
 
 
Followed by a final extension at 72ºC for 8min and stored at 4ºC to process for internal 
amplification round. 
 
 
3.9.2 Internal/nested PCR run 
Internal PCR was carried out in identical manner except that internal set of primers were 
used and few other modifications in PCR amplification programme. 
• Internal primers were used as described in section 3.8.2 
• Annealing temperatures was used 65ºC during amplification of IgG and IgM  specific 
amplification while 55ºCfor IgA specific amplification 
• External PCR product was used as template 
• Numbers of cycles were reduced to 40. 
 
Amplified DNA was put at 4ºC to be used in next step to visualize PCR specific products on 
Agarose gel and purification. 
 
Longterm impact of anti-CD20 mediated transient B cell depletion on memory B cells in patients with RA 
 
42 
 
3.10Visulization of PCR product and DNA isolation from Agarose gel 
 
All nested PCR products were run on 1.5% Ultra pure agarose electrophoresis 
gel(GIBCO,BRL) for an hour at 100V and visualized with ethidium bromide (0.5µg/ml, 
sigma) under UV light at wavelength of 254nm. As shown in Fig.3.1, positive bands (around 
350bp) were selected for further purification and cut from agarose gel. 
The products excision was carried out with a clean scalpel and purified by using 
MinElute Gel Extraction Kit (Qiagen) according to manufacturer’s manual instructions. 
MinElute Gel extraction combines the convenience of spin-column technology having 
specific binding properties of a uniquely designed silica gel membrane. DNA absorbs to the 
membrane. These columns are designed to give high-end concentration of purified DNA 
fragments elution in water. Impurities are efficiently washed away. 
The procedure includes dissolving agarose, binding DNA to silica membrane, washing with 
different buffers and finally extracting in 10µl water. 
 
 
 
 
 
Figure 3.1 Agarose gel; showing 350bp region corresponding to Ig-VH3 specific products. 
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3.11 Sequence Reaction 
Purified PCR products were processed for sequence reaction prior to sequencing. 
Sequence reaction was performed by using ABI PRISM® BigDye™ Terminators v 3.0 
Sequencing Ready Reaction Kit (Applied Biosystems). 
This kit contains premixed deoxynucleotide triphosphates, AmpliTaq DNA polymerase, FS, 
dTth pyrophosphatase (a component in AmpliTaq DNA Polymerase, FS), dye terminators, 
magnesium chloride and buffers which provide a fluorescent-based cycle sequencing reaction.  
 
Sequence reaction mixture 
The sequence reaction mixture contains  
4µl of ABI PRISM® BigDye™ Terminator 
3.5µl of purified DNA template 
0.5µl of paint pellet blue dye 
11.5µl dH2O 
0.5 µl of sequencing primer (10pmol/µl) 
 
In case of Ig-VH3 sequence reaction the sequencing primer is nested VH3 primer and in case 
of Isotype studies VH1-VH6 mixed primer was used at concentration 10pmol/µl. 
The cycling parameters were 
 
1 cycle 
 
 
 
25cycles 
 
 
Followed by a final extension at 72ºC for 5min and stored at 4ºC 
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3.12 Purification of sequence reaction products 
 
3.12.1 AutoSeq Column purification 
Sequencing needs a highly purified DNA material so a lot of care is taken with PCR 
products after sequence reaction to extra purify them from different debries. So the PCR 
products were first purified by passing through the AutoSeq G50 columns (GE 
Healthcare).This process removes the excess dye-labelled dideoxynucleotides from the 
sequence reactions. 
Procedure: First resin columns were vortexed gently and resin preservative was removed 
before spinning columns at 2000g for 1min followed by loading the PCR products at the 
centre of the angled surface of resin compact bed and columns were spun subsequently for 
1min at 2000g to collect purified DNA in a separate eppendorf tube. 
 
3.12.2 Isopropanol precipitation 
A further purification of PCR products was carried out by precipitating with 75% 
Isopropanol. For this purpose 75µl of Isopropanol was added to total 25 µl column purified 
PCR product and put in room temperature for 15min after gentle mixing. After incubation, 
samples were centrifuged at maximum speed of 14000rpm for 20min.The supernatants were 
discarded and pellets were suspended again in 250 µl of 75% Isopropanol and centrifuged at 
same speed for 10min.The supernatant was discarded followed by pellets drying at 40ºC for 
1-2 min after air-dry. These pellets were dissolved in 20 µl Template Suppression Reagent 
(Applied Biosystems),denatured at 95ºC for 3min and place on ice for 5min or until further 
processing. 
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3.13 An overview of Single B cells sorting 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2 A schematic representation of single cell sorting technique 
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3.14 Sequencing 
Finally samples were sequenced on an automated ABI PRISM 310 Genetic Analyser 
(Applied Biosystems).Sequencing was carried out by using POP6 Polymer reagent. 
 
3.15 Sequence analysis of Ig sequences 
Sequence analysis was carried out by using online web-based software programme 
JOINSOLVER (http://joinsolver.niams.nih.gov/index.htm) which was created by National 
Institute of Health (NIH), National institute of Arthritis and Musculoskeletal and Skin Disease 
(NIAM) and centre for information technology (CIT). It is used for human immunoglobulin 
V(D)J recombination, their nucleotide and amino acid alignment, extensive mutational 
analysis and CDR3 analysis and summarizes results in different forms.  
Following parameters were analyzed in our study. 
1. Mutational frequency 
Total number of mutations in the variable region was determined during sequence analyzed 
by comparing the germline sequence. Mutational frequency was calculated by dividing the 
number of mutations by total nucleotides in the rearrangement, multiplied by 100. 
2. VDJ segments usage 
In each Ig rearrangement, the heavy chain variable region analysis was undertaken. The 
variable gene used in every rearrangement was delineated. 
4. CDR3 length 
CDR3 region is actively participant of antigen binding. CDR3 length was calculated by 
determining number of nucleotides from residue 95-102. CDR3 was calculated by using 
Joinsolver only software. 
3. Mutations in RGYW and WRCY motifs 
As shown by previous studies presence of predefined RGYW/WRCY (R = purine, Y= 
pyrimidine and W= A/T) mutational hotspot motifs (Dörner et al, 1998; Farner et al, 1999) 
which are believed to undergo somatic hypermutation particularly during T-B cell interactions 
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in germinal center. The number of mutations lying in the hotspot motifs was assessed and the 
percentage of RGYW/WRCY mutations was calculated. 
An example of such results is shown down. 
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A representative sequence analyzed on Joinsolver showing FR/CDR regions and 
summarized results 
 
 
3.16 Statistical analysis 
Statistical analysis was performed by using GraphPad Prism 3.03 (GraphPad Software, San 
Diego, CA, USA). Analysis of FACS data, mutational differences and CDR3 length 
differences were calculated by non parametric Mann-Whitney U test. Mutational frequencies 
were calculated by using online GraphPad quick calculator (www.graphpad.com). P values 
<0.05 was considered to be significant. 
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3.17 Materials 
Media and reagents 
Ficoll-paque (Amersham Biosciences) 
HBSS (Gibco BRL) 
RPMI 1640(Sigma) 
Trypan Blue (Merck) 
Penicillin-streptomycin (Biochrom AG) 
L-glutamine (Gibco BRL) 
Kanamycin (USB Corporation) 
Agarose gel 
1.5% Agarose Ultrapure (Gibco BRL) 
1X TAE buffer 
0.5µg/ml ethidium bromide 
 
Buffers 
TAE electrophoresis buffer(50X)    242g Tris base 
        57.1ml glacial acetic acid 
        100 ml 0.5M EDTA(pH 8.0) 
         
Loading dye(6X)      0.25% bromophenol blue 
        0.25% xylem cyanol 
        30% glycerol in water 
LoTE(3mM Tris,0.2 mM EDTA)    20µl EDTA 0.5M pH 8 
        made upto 50ml with water  
TE(10 mM Tris,1mM EDTA)    100µl EDTA 0.5 M pH8 
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        500µl Tris 1M 
        Made upto 50ml with water 
Sequencer 
Genetic analyzer buffer (Applied Biosystems) 
Pop-6 gel (Applied Biosystems) 
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4. Results 
 
4.1 Identification of peripheral blood memory B cell subsets 
Human peripheral blood B cells can be segregated into two populations on basis of 
surface expression of IgD and CD27 as follows: 1) a large population of IgD+CD27- fraction 
represents mature naïve B cells(D4) and 2)CD27+ memory population which can be separated 
into IgD+ memory B cells (pre/non-class switched memory)and IgD- (class-switched memory) 
subsets. The FACS plot (Figure 4.1) below shows different memory subpopulations based on 
3 colour staining showing D1 as class-switched memory B cells and D2 as pre-switched 
memory B cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Different B cell subsets. Showing naïve B cells in D4 while pre and post-
switched memory B cells in compartment D1 and D2 respectively. 
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4.2 Peripheral blood CD27+ memory B cells in patients with RA  
 
To assess any significant changes in memory B cells pool in patients with rheumatoid 
arthritis, we analysed memory B cell subpopulations in 33 patients with rheumatoid arthritis 
as well as in 22 normal donors. We find no significant differences between mean percentages 
of IgD+CD27+ memory populations in CD19+B cell pool in patients with RA and ND (Figure 
4.2a). %Mean CD27+IgD- memory B cells population was observed 21.3±1.85% which were 
non-significantly increased in RA patients (Figure 4.2b) than normal donors 17.2±1.9% which 
confers a similarity in memory B cell pools in rheumatic patients and ND. 
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Figure 4.2 Frequency of pre and post-switched memory B cells. Peripheral CD19+ gated 
comparative frequency of (A) IgD+CD27+ and (B) IgD-CD27+ memory B cells in patients 
with rheumatoid arthritis and healthy donors. 
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4.3 CD21 surface expression of IgD+ memory B cells  
Human splenic marginal zone B cells are distinguished from naïve and class-switched 
memory B cells on basis of different surface markers IgMhighIgDlowCD21highCD23low.Previous 
research has shown that a population of CD27+IgD+ memory B cells in peripheral blood 
represents circulating marginal zone B cells and these cells could also be recognized on basis 
of CD21+, CD23- and CD1c high surface expression (Weller et al, 2004). 
Therefore we addressed whether all CD27+IgD+ memory B cells belong to circulating 
marginal zone B cell subset on the basis of CD21 surface expression. We analyzed 
IgD+CD27+ B cells from 13 healthy donors and 22 RA patients for expression of CD21 
surface molecule by  4 colour FACS staining and found majority ( > 90%)of IgD+CD27+ B 
cells were CD21+ and very small population was CD21 negative. There was no difference 
between RA patients and healthy donors.  
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Figure 4.3 Percent expression of CD21+/- population. Normal donors and RA patients gated 
on IgD+CD27+ memory B cells. 
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4.4 Mutational pattern of IgD+CD27+CD21+/- memory B cells 
As we found majority of IgD+ memory B cells expressing CD21 surface marker, so addressed 
the question whether low and high mutated pattern of IgD+ memory B cells could be 
segregated on the basis of CD21 expression as seen in healthy donors and RA patients. For 
this purpose, we sorted IgD+CD27+CD21+/- memory B subsets from a healthy donor and 
looked in Ig-VH3 mutational pattern. 
As shown in figure 4.4, no significant difference was observed in these populations on basis 
of mutational load in their IgR indicated highly homogenous population. These findings 
indicate that acquisition of mutations in IgD+ memory B cells is not dependent on CD21 
molecule. 
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Figure 4.4 Mutational patterns of IgD+CD27+CD21+/- memory B cells. No significant 
changes in their Ig receptor (S= number of analyzed sequences) mutations were observed. 
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4.5 Mutational pattern of IgD+CD27+CD23+/- memory B cells 
Similar to CD21 marker, we also checked IgD+ memory B cell expression of CD23 and sorted 
CD23+ and negative CD27+IgD+ B cells and looked in their mutational pattern as shown in 
figure 4.5. We found no difference in acquisition of mutations in IgR depending on 
CD23.From these findings we could conclude that low and high mutational pattern of IgD+ 
memory B cells in independent of surface markers specific for circulating marginal zone B 
cells. 
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Figure 4.5 Mutations/sequence of IgD+CD27+CD23+/- B cells. Mutational pattern of 
IgD+CD27+CD23+/- memory B cells sowing similarity in their Ig receptor (S= number of 
analyzed sequences) mutations. 
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4.6 A diversified IgR mutational pattern of IgD+ memory population 
 
To assess the immunoglobulin receptor (IgR) mutational behaviour of IgD+/CD27+ 
memory B cells, we studied VH3 family genes in IgD+ memory B cells sorted from 7 patients 
with active rheumatoid arthritis before undergoing rituximab therapy along with 4 healthy 
individuals chosen to make comparative study for assessment of disease induced changes in 
IgR of IgD+ memory B cell subset. Ig-VH3 family was amplified by using single B cell sorting 
technology followed by nested PCR. Single cell sorting is most reliable technique to study 
single cell behaviour in more accurate way. We analysed 248 rearranged Ig-VH3 gene 
sequences from individual IgD+ memory B cells population (shown in Figure 4.6) collected 
from RA patients and healthy donors (HD). Ig-VH3 family was selected for our study based 
on the fact that it is largest and dominant subfamily among variable genes of IgR heavy chain 
(Brezinschek et al, 1995; Rouziere et al, 2005). Only productive sequences were included in 
study for further analysis. The frequency of IgD+CD27+ memory B cells was on average 15% 
of total CD19 positive B cells in both RA and ND. 
 
  The Ig-VH3 gene study showed that IgD+ memory B cells display a diversified 
mutational pattern (Figure 4.6) including non-mutated, low mutated and high mutated 
sequences. It collectively revealed 88% of mutated rearranged Ig-VH3 sequences with an 
overall mutational frequency 3.83±0.19% (mean±SEM) and only 12% non-mutated 
sequences. Depending on the number of mutations/sequence as proposed by Palanichamy 
(Palanichamy et al, 2008), we can further categories mutated sequences into low and high 
mutated sequences (median= 9mutations/sequence). Among all mutated sequences, 52% of 
IgR had high mutations i-e >9 mutations/sequence while 48% were low mutated i-e ≤ 9 
mutations/sequence. A similar mutational load was observed in IgR in 4 healthy donors as 
shown in Figure 4.6. In total 199 rearranged sequences showed 90% mutated sequences with 
an overall mutational frequency 3.77±0.27% while 10 % non-mutated IgVH3 sequences. 
These results indicate a similar mutational frequency of IgD+ memory B cells in patients with 
rheumatoid arthritis and healthy donors. 
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Figure 4.6 IgD+ memory B cells in HD and RA. Showing a diverse expression of mutations 
in Ig-VH3 Family.  A comparative expression of RA patients and healthy donor (HD) 
showing similar mutational behaviour (S=number of analyzed IgR sequences, n= number of 
studied individuals). 
 
4.7 Rituximab mediated modulation of Ig-VH3 receptors of IgD+ memory B 
cells  
Rituximab causes selective depletion of CD20+ B cells from periphery and secondary 
lymphoid organs. B cells in periphery remain diminished over a period from 6-12 months 
while a marked reduction of memory B cells have been reported previously  among which  
IgD+ memory B cells repopulate specifically slow in different memory B cell populations 
during regeneration in rheumatic patients (Roll et al, 2006). So our specific interest developed 
to observe changes in their IgR during regeneration , we investigated nine patients in detail at 
specified time points during B cells repletion phase over a period of six years and find 
interesting dramatic changes in mutational behaviour in Ig-VH3 receptors. During the first 
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year after rituximab therapy IgD+CD27+ B cells are generally not detectable. After one year 
IgD+ memory B cells could be found in periphery. Figure 4.11 shows in detail summary of 
mutational load in IgR of individual IgD+ memory cells studied a 6 years (results a-d) time 
course after anti-CD 20 mediated B cell depletion. 
a) One year after rituximab 
Among 7 patients treated with rituximab, 3 patients were followed one year after B 
cells depletion. During first year of regeneration phase IgD+ memory B cells showed highly 
different mutational load in their IgR in comparison to pre-depletion phase. Total 82 
sequences analysed from 3 patients showed that 84% of rearranged Ig-VH3 sequences 
harboured no mutations at all which were 12% before therapy (P=0.0001) as shown in figure 
4.7. Further discrimination showed only low mutated sequences (16%) while highly mutated 
sequences were completely absent during 1st year of regeneration phase (52% before therapy, 
P=0.0001). This marked absence of highly mutated sequences was further assessed in patient 
treated two years before with rituximab. 
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Figure 4.7 Acquisition of mutations in single IgR one year after rituximab. Mutational 
pattern of single IgD+ memory B cells in comparison to pre-therapy showing marked 
reduction of mutational load (S=number of analyzed IgR sequences). 
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b) Two years after rituximab 
We analyzed one patient two years after B cell depletion. As shown in Figure 4.8; IgD+ 
memory B cells acquired few mutations in second year of repletion phase. Figure shows 
individual sequences harbouring mutations in their IgR in this time point but still showing 
very few high mutated sequences. In total 40 analysed sequences, we could observed only 
7.8% highly mutated (P=0.0001 as compared to before therapy) sequences. Rest of sequences 
comprised 79.2% non-mutated while 13% were low mutated sequences. This time point was 
quite interesting because total B cell numbers were normalized in periphery but IgD+ B cells 
were still reduced. 
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Figure 4.8 Acquisition of mutations in single IgR two years after rituximab. Majority of 
low or non mutated sequences were recovered two years after RTX(S=number of analyzed 
IgR sequences). 
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c) Four years after rituximab 
A longitudinal follow up of two patients after 4 years treatment with RTX again indicated that 
IgD+  memory cells did not get their pre-treatment IgR expression (as before therapy) and Ig-
VH3 family sequences (50 sequences in total) showed that only 14% of highly mutated 
sequences were recovered even 4 years (Figure 4.9) after B cell depletion (P=0.0001).But on 
the other hand, frequency of non-mutated sequences decreased to 40.5% but still higher than 
pre-treatment while frequency of low mutated sequences got normal i-e 45.5% (as before 
therapy).This showed that rituximab directed B cell depletion not only hampered regeneration 
of IgD+ memory B cells but also acquisition of mutations in their Ig receptors lead us to 
further explore this phenomenon in patients treated with rituximab in later time point.   
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Figure 4.9 Acquisition of mutations in single IgR 4 years after rituximab.14% high 
mutated sequences (S=number of analyzed IgR sequences) were recovered (52% pre-
treatment, P=0.0001) 
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d) Six years after rituximab 
As we find already that IgD+ memory B cells show a skewed mutations in their IgR, so we 
proceeding to study these cells in patients treated long ago with rituximab. So we studied 
mutational pattern in 3 patients treated with rituximab 6 years ago. Even long after treatment, 
not only IgD+ memory population was diminished on basis of cell numbers in overall memory 
B cell pool but also significant reduction in highly mutated sequences in Ig-VH3 receptors was 
observed. In detail, out of 74 analyzed (Figure 4.10) sequences, total 75% mutated sequences 
were recovered (88% pre-treatment, P=0.0001) in which only 25% highly mutated sequences 
were acquired which were still diminished than before therapy (P=0.0001). Overall B cell 
count of CD19 positive B cells was normalized 2years after rituximab, IgD+CD27+ B cells 
were still below 5% of total CD19+ B cells 6 years after therapy. These results clearly indicate 
that rituximab directly B cell depletion has great impact on the mutational acquisition of IgD+ 
memory B cells.  
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Figure 4.10 Acquisition of mutations in single IgR 6 years after rituximab. IgD+ memory 
B cells showing recovery of low mutated sequences while high mutated sequences were still 
not normalized(S=number of analyzed IgR sequences). 
 
Longterm impact of anti-CD20 mediated transient B cell depletion on memory B cells in patients with RA 
 
62 
 
 
 
Summary  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.11 Mutations/sequence of VH3 gene rearrangements expressed by individual 
IgD+ memory B cells after rituximab therapy: showing a reduction of highly mutated 
sequences (as compared to pre-depletion) over a course of 6 year follow up(S= number of 
analyzed IgR sequences, n= number of studied individuals) in RA patients treated with 
rituximab. (   P = 0.0001 versus before therapy) 
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4.8 IgD+ memory B cells in SLE patient after rituximab 
To evaluate effect of anti-CD20 mediated B cell depletion on IgD+ memory B cells in a 
disease independent manner, we analyzed one patient with systemic lupus erythematosus 
(SLE) treated with rituximab. Results shown in Figure 4.12 indicate clearly that rituximab 
treated RA and SLE patient showed no difference in acquisition f mutations in their IgR and 
showed similar mutational frequency. The affected reduced mutational rate of IgD+ memory 
B cells after anti-CD-20 mediated B cell depletion by itself seems not to be related to RA or 
ongoing methotrexate therapy as in SLE patient no additional immunosuppressive treatment 
was given and brought same pattern of mutations in IgD+ memory B cells. These results 
clearly indicated that rituximab hinders these cells in acquiring not only normal peripheral 
pool but also acquisition of mutations in their IgR. 
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Figure 4.12 Number of mutations in single IgR 4 years after rituximab in SLE and RA. 
Mutational pattern of IgD+ memory B cells in patients with RA and SLE showing similar 
mutational acquisition in their IgR at same time span. 
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4.9 Significant increase in CDR3 length after rituximab 
 
By using IgR sequence analysis approach to study IgD+ memory B cells during 
rituximab therapy, other parameters were also checked and found interesting changes in them 
as well, CDR3 length comparison was one of them. CDR3 region is actively participant of 
antigen binding. CDR3 length was calculated by determining number of nucleotides from 
residue 95-102. CDR3 lengths were compared at above described Ig-VH3 receptor study time 
points by using Mann-Whitney U test. A mean length of CDR3 region before therapy (Figure 
4.13 ) was 43±0.89 bp which increased to 49±1.17bp during early repletion phase (P=0.0002) 
and consistently elevated in IgD+ memory B cells during 2 years (mean 49±1.61, P=0.0014) 
and 4 years (mean 50±1.54bp, P=0.0010) follow up.CDR3 length was even not normalized 
after 6 years (mean 48±1.3bp, P=0.0080).These results indicate that transient B cell depletion 
therapy have selective pressure on the IgD+ memory cell’s CDR3 length which is major 
antigen binding site. These results may also develop the hypothesis that after B cell depletion 
phase, these regenerated IgD+ memory B cells particularly represents ontogeny. 
 
While analyzing CDR3 expression by different sequence subsets categorically based 
on acquisition of mutations, an increased CDR3 length was only contributed by non-mutated 
Ig receptors and a decreased CDR3 length was observed in low and high mutated sequences. 
An increased CDR3 (Figure 4.14) length was participated by due to majority of non-mutated 
sequences contribute in 6 years follow up after rituximab. 
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Figure 4.13 Significantly increased CDR3 length in regenerated IgD+ memory B cells:     
(    P ≤ 0.0025 versus before therapy). The CDR3 length did not normalize even after 6 years 
compared to the values prior to therapy.CDR3 length was analyzed from sequences shown in 
Fig.4.11. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14 Distribution of CDR3 length in non-mutated (NMUT), low mutated (LMUT) 
and high mutated (HMUT) sequences. Significantly increased CDR3 length is only 
associated with non- mutated sequences. 
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4.10 V, D and J gene segments usage during repletion of IgD+ memory B 
cells 
 
To access any prominent shift in V, D and J gene usage in VH gene recombination 
phase during repletion of IgD+ memory B cells, we studied pre and post-treatment IgVH3 
sequences in same patients. Before therapy, a variety of ten VH3 mini-genes were expressed 
while two of them comprised 50% of all VH3 rearrangement (VH3-23, 35%; VH3-30, 15%). 
During regeneration phase, a significant increased use of VH3-23 was observed (50%, 
P=0.0449) while most of VH3 mini-genes were observed unaffected in regenerated IgD+ 
memory B cells. 
No significant changes were observed in D gene usage during repopulation phase and 
large varieties of D genes were present before and after treatment without any prominent 
usage. Analysis of JH segments showed unaffected distribution of these segments during 
regeneration.JH4 gene was represented most frequently. 
 
 
Table 4.1 Difference in VH3 minigene usage during rituximab 
 
VH3 subfamily Before rituximab (%) After rituximab (%) 
VH3-23 35 50 
VH3-30 15 12 
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4.11 Class-switched memory B cells during rituximab therapy 
 
During memory B cells development, class-switching is an important process. These 
class-switched IgD-CD27+ memory B cells are believed to undergo somatic hypermutation in 
pre-defined germinal centres. Previous studies showed an overall reduction of memory B cells 
after rituximab therapy (Roll et al, 2006; Anolik et al, 2007) and as we find interesting 
changes in mutational pattern of pre-switched memory B cells during anti-CD20 medicated B 
cell depletion so class-switched memory B cells became our great interest to study. To 
elucidate effect of rituximab on mutational pattern of these cells, we studied them pre and 1 
year post treatment in two patients and results are shown in figure 4.15. Although overall 
memory B cells were diminished after anti-CD20 therapy but single IgD-CD27+ memory B 
cell analysis showed that in contrary to IgD+ memory B cells, IgD-CD27+ memory B cells 
harboured quantitatively similar mutations (an average 18 mutations/sequence) in their IgR 
during repletion phase (median 18mutations/sequence in IgD-/CD27+ vs. median 9 
mutations/sequence in IgD+/CD27+; P=0.0001) and no expressional difference was observed 
in pre and post-treatment repopulations. These results not only gave comparative results but 
also indicated that in class-switched memory B cells, the process of somatic hypermutation is 
not affected by B cell depletion and clearly indicate that these two memory B cell population 
mature in different sites. 
Similar to the mutational frequency, class-switched memory B cells did not exhibit an 
increase in their CDR3 length as shown in figure 4.16. We observed 43±1.63bp CDR3 length 
in class-switched memory B cells which was non-significantly decreased to 40.5±1.84bp after 
anti-CD20 mediated B cell depletion therapy. 
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Figure 4.15 Mutational pattern of IgD-CD27+ memory B cells during rituximab therapy. 
Results show a similar IgR mutational acquisition(S=number of analyzed sequences). 
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Figure 4.16 CDR3 in class-switched memory B cells during rituximab. In accordance with 
mutational pattern of class-switched memory B cells in fig. 4.15, no significant change of 
CDR3 length was observed during rituximab therapy 
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4.12 V, D and J gene usage in class-switched memory B cells 
To access any prominent shift in V, D and J gene usage in VH gene recombination 
phase during repletion of class-switched memory B cells, we studied pre and post-treatment 
IgVH3 sequences in same patients. Before therapy, a variety of eleven VH3 mini-genes were 
expressed which showed consistency during repletion phase and no prominent use of 
particular mini-gene was observed. 
No significant changes were observed in D gene usage during repopulation phase and 
large varieties of D genes were present before and after treatment without any prominent 
usage. Analysis of JH segments showed unaffected distribution of these segments during 
regeneration. JH4 gene was represented most frequently. 
 
4.13 Mutations in hotspot motif RGYW/WRCY during rituximab 
To evaluate modulation of class-switched memory B cells, we focused on mutations into pre-
defined hotspot motifs RGYW and WRCY (R= purine, Y= pyrimidine, W=A/T) along Ig 
rearrangements(Dörner et al, 1998; Farner et al, 1999)  was assessed in these cells circulating 
before therapy and one year after rituximab therapy. As shown in the figure 4.17, class-
switched memory B cells showed a reduced mutational targeting of RGYW/WRCY motifs 
before therapy in comparison to after therapy status. A significantly higher number of 
mutations were confined to the RGYW/WRCY motifs during repletion phase. Of note, class-
switched memory B cells showed 27% mutations in RGYW/WRCY motifs before treatment 
which was significantly increased to 43% after therapy (P=0.0003) 
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Figure 4.17 Average RGYW/WRCY targeting in one patient before and after therapy. 
Significantly RGYW/WRCY increased mutational targeting was observed. P value calculated 
by chi square test. 
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4.14 IgD+ memory B cells after allogeneic stem cell transplantation 
As slow acquisition of mutations in individual IgR was observed in IgD+ memory B 
cells only after transient B cell depletion, so we addressed how acquisition of mutations 
developed in these cells after allogeneic stem cell transplantation? So we selected 3 patients 
treated with high dose chemotherapy including total body irradiation followed by allogeneic 
stem cell transplantation (ASCT). 
Figure 4.18 illustrates Ig-VH3 family studied in 3 allogeneic SCT patients included in 
study one year after treatment. In detail, we analyzed 85 productive VH3 sequences and found 
that 41% non-mutated sequences (35 out of 85 sequences) which were significantly lower 
than RA (84% in RA verses 41%, P=0.0001).In rest of mutated sequences, 17.5% sequences 
acquired higher mutation and 41.5% low mutation sequences were present which clearly 
indicates that in allogeneic stem cell transplant patients these IgD+ memory cells repopulate in 
normal pattern. This data concludes that temporal B cell depletion by rituximab has more 
pronounced effect on IgD+ memory B cell arm among CD19+ B cells during repletion phase. 
In line to mutational data, CDR3 length was significant between two groups i-e ASCT 
patients showed a normal (in accordance to HD) CDR3 length than RA patients (Figure 4.19). 
CDR3 length in IgD+ memory B cells from ASCT patients had mean length of 45.86 ± 1.04 
bp  significantly lower than RA patients 49.30 ± 1.16 bp (P=0.0280) but in line with healthy 
donors. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.18 Individual IgR of IgD+ memory B cells in Allogenic SCT vs. RA. 3 patients 
after RTX and 3 patients after ASCT (S=number of analyzed IgR sequences, n= number of 
studied individuals) showing significant different in IgR mutational pattern. 
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Figure 4.19 CDR3 length in allogenic SCT vs.RA.CDR3 length was shorter in ASCT 
regenerated IgD+ memory cells in comparison to those from RA patients. 
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4.15 Class-switched memory B cells after ASCT 
As seen previously in RA patients after rituximab (Figure 4.15), Ig receptors harboured 
unaffected quantitatively similar mutational pattern in patients after allogeneic stem cell 
transplantation emphasizing our previous findings (Figure 4.20).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20 Mutations/sequence of class-switched memory B cells after rituximab and 
after ASCT. No quantitative difference in the number of mutations were in allogeneic stem 
cell transplant patients as seen previously in RA (S=number of analyzed IgR sequences, n= 
number of studied individuals). 
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4.16 Autologous stem cell transplantation 
As we observed improved regeneration and mutational pattern of IgD+ memory B cells 
in allogeneic SCT patients (figure 4.18) in comparison to B cell depletive therapy, we 
analyzed IgD+ memory B cells in patients undergone autologous stem cell transplantation 
(SCT). With this type of transplant, the patient's stem cells are obtained prior to high-dose 
chemotherapy, frozen, and stored and are then given back afterward.  
We analyzed IgD+CD27+ memory B cells from two patients one year after autologous 
SCT. The results are shown in figure 4.21. We found a non-significant correlation between 
acquisition of mutations in IgD+ cells from patients undergoing autologous SCT and 
allogeneic SCT. But on the otherhand, the number of mutations in IgD+ memory B cells in 
autologous SCT was significantly high compared to rituximab treated RA patients studied at 
same time point. They showed mutational frequency 6.44 ± 2.41% vs. 0.35 ± 0.11% in RA 
(P=0.0001). All these results collectively indicated that rituximab mediated B cell depletion 
exerts strong impact on somatic hypermutation in IgD+ memory cells. 
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Figure 4.21 Number of mutations/sequence in IgD+ memory B cells 1 year after 
autologous SCT in comparison to anti-CD20 treatment and ASCT. Individual IgR of IgD+ 
memory B cells were analyzed from 3 patients after RTX,3 patients with allogeneic SCT and 
2 patients after autologous SCT showing significant different in IgR mutational pattern. 
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4.17 Modulation of Ig-Isotypes during rituximab 
Memory B cells expressing CD27 surface molecule and undergoing somatic 
hypermutation in immunoglobulin variable (V) region classically switch from initial 
expression of IgM to that of other Ig classes resulting in surface expression of IgG, IgA or IgE 
and lack surface expression of IgD and CD38 ( Shi et al, 2003) . In healthy adults, more than 
half of CD27+ B cells are class-switch cells (mainly IgG or IgA surface expression), while the 
remaining are IgD+ memory cells. Therefore we addressed the question whether anti-CD20 
mediated B cell depletion induce any change in process of classical isotype switching in IgD-
CD27+ memory B cells  in two patients undergoing rituximab therapy. We focused mainly all 
IgG and IgA by using single cell sorting technique to assess their percentages in memory B 
cells after amplified VH1-VH6 families by nested PCR. 
As shown in figure 4.22& 4.23 IgA and IgG expressing single memory B cells are 
equally distributed before therapy. However after rituximab therapy class-.switched memory 
B cells were predominantly of IgA isotype. We find 50% of IgA expressing B cells before 
therapy which increased to 76% during first year of B cell repletion phase (P=0.0001).  
On the otherhand, IgG expressing class-switched memory B cell                                            
decreased from 50% to 24% (P=0.0001). These results indicated that rituximab also 
modulated isotype switching in memory B cells resulted increase in IgA producing cells. 
We closely observed immunoglobulin variable (V) gene usage during rituximab 
therapy in these IgA and IgG producing B cells and find no characteristic changes in usage of 
VH sub-families during B cell repletion phase as shown in table 4.2. 
 
Table 4.2: Usage of VH subfamilies during pre and post-RTX treatment 
VH subfamilies Before rituximab (%) After rituximab (%) 
VH1 
VH2 
VH3 
VH4 
VH5 
11  
7 
50 
25 
7 
19 
3 
54 
20 
4 
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Figure 4.22 Modulation of IgD-CD27+ memory B cells producing IgG. A reduced number 
of IgG producing memory B cells recovered one year after rituximab. 
 
 
 
 
 
 
 
 
 
 
 n=2 n=2 
Figure 4.23 Modulation of IgD-CD27+ memory B cells producing IgA. A significantly 
increased number of IgA producing memory B cells recovered one year after rituximab. 
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5. Discussion 
Human B cells play a critical role in the pathophysiology of different autoimmune 
diseases. In addition to secretion of autoantibodies and proinflammatory cytokines 
(interleukin 1, 6 and 10, TNF-α and lymphotoxin α/β), they efficiently take up,  process and 
present autoantigens and influence the formation of T cell dependent niches (Silverman et al, 
2003; Hansen et al, 2007). Therefore approaches to target B lymphocytes directly or 
indirectly are developed for clinical practice. In this context, transient B cell depletion by the 
anti-CD20 specific monoclonal antibody (rituximab) has shown promising results in treating 
patients with autoimmune diseases including rheumatoid arthritis, SLE and systemic 
vasculitis (Leandro et al, 2006; Browning, 2006; Cohen, 2008). 
 
B cell regeneration data after therapeutic B cell depletion with rituximab revealed a 
characteristic repletion pattern that seems to recapitulate B cell ontogeny. In the early stages 
of peripheral B cell repopulation increased numbers of transitional B cells are followed by B 
cells with naïve phenotype (Roll et al, 2006&2008; Anolik et al, 2007). Although peripheral 
B cell numbers normalize in most patients between one and two years after a single course of 
rituximab a longterm reduction of memory B cells, particularly the IgD+CD27+ memory 
subset, has been observed (Roll et al, 2006). In a prospective clinical study our laboratory has 
shown previously that the overall number of memory B cells correlates well to the duration of 
clinical response to rituximab. Moreover the early regeneration of IgD+CD27+ memory B 
cells could be linked to nonresponse to rituximab therapy (Roll et al, 2008). These findings 
developed our specific interest for the molecular study of B cell receptors in memory B cells 
study during B cell repletion after rituximab. Therefore the prime aim of the current study was 
to search for BCR gene modulations in memory B cell subsets after B cell recovery which 
may provide insights into a longterm molecular impact of rituximab. We explored in detail the 
somatic mutational frequency and pattern of Ig-VH3 gene rearrangements among pre- and 
post-switched memory B cells before and up to 6 years after rituximab therapy.  
 
The phenotypic analysis of peripheral pre-switched (IgD+CD27+) and post-switched 
(IgD-CD27+) memory B cells did not reveal any quantitative differences in RA patients 
(n=33) prior to B cell depletion therapy compared to healthy donors (n=22) (Figure 4.2). In a 
previous study overall increase in IgD-CD27+ memory B cells were described in RA patients 
(Fekete et al, 2007) but no change in IgD+ memory B cells was observed. Our study showed 
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non-significant increase in class-switched memory B cells as well. This difference may be 
attributed to different treatment methods in patients’ cohort and disease duration. We 
extended those studies in directly analysing the B cell Ig receptor in single B cells of RA 
patients and healthy controls. The mutational analysis of individual Ig receptors in pre-
switched memory B cells in rheumatic patients (n=7) showed no difference in acquisition of 
mutations in comparison to healthy donors (n=4) (Figure 4.6). In these studies no obvious 
selective pressure could be identified on these cells by disease itself or by the stable 
concomitant low dose methotrexate (MTX) treatment. 
 
However comparing pre-switched and post-switched memory B cells a highly 
significant difference in the amount of mutations can be seen. The population of IgD+CD27+ 
memory B cells is comprised of non-mutated, low and highly mutated (median= 9 
mutations/sequence) rearranged Ig receptors while the IgD-CD27+ memory B cell 
compartment shows quite uniformly highly mutated sequences (median 
18mutations/sequence)  indicating a significant difference between these two groups of 
memory B cells (mutational frequencies 3.83±0.19% vs. 7.1±0.53%; P=0.0001). The presence 
of a significant proportion of ~12% of non-mutated Ig sequences in IgD+CD27+ memory B 
cells (Figure 4.6) in both healthy and RA patients suggests that these cells are still under a 
diversification process which is not seen in post-switched CD27 expressing B cells. These 
findings indicate that the two memory subpopulations may have different sites of origin and 
diversification. For class switched memory B cells it is known that they are generated in 
germinal centres directly involving T cell dependent responses against antigen (Klein et al, 
1998). The origin of IgD+ memory B cells is still debated. Due to their phenotype 
(IgD+CD27+IgM+CD23-CD21highCD1c+) they have been correlated as a circulating 
counterpart of marginal zone B cells (Weller et al, 2004). In our analyses > 90% of these cells 
express CD21high CD23low/-.  With regard to the Ig receptor mutations, non- and mutated-Ig 
receptors were non-selectively distributed among CD21+/- CD23+/- IgD+ memory B cells. A 
recent study (Weller et al, 2008) has provided clear evidence for the presence of IgD+ 
memory B cells already in infants below 2 years of age. With increasing age Ig receptor 
mutations increase from 60% to 83% in IgD+ memory B cells. These data correspond well 
with our findings where in adults 88% mutated sequences were found within the IgD+ / 
CD27+ subset. This indicates continuously slowly ongoing somatic hypermutation with age. 
In contrast, within the class-switched IgD-CD27+ memory B cells more than 95% showed 
mutated sequences with high mutational frequency. 
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So far the development and process of somatic hypermutation in IgD+ memory B cells 
are not so clear. Previous studies have suggested that development of somatically mutated 
IgD+ memory B cells does not require CD40 or CD40L interactions (Razanajaona et al, 1996) 
as the presence of these cells in patients with germinal centre (GC) development defects have 
been observed (Salzer et al, 2006;Tangye et al, 2007;Weill et al, 2004).  Hyper-IgM patients 
possess IgD+ memory B cells but lack class switched memory B cells (Weller et al, 2001). 
Also the mutational frequency of IgD+ /CD27+ cells in hyper IgM patients was similar to that 
seen in healthy donors. It has been suggested that mutated IgD+ memory B cells are 
developmentally dedicated to T cell independent responses because these cells were found to 
be localized in the marginal zone of spleen, a site where in rodents typically thymus 
independent (TI) responses develop (Martin et al,2000).  This idea is also supported from 
studies where IgD+ memory B cells were completely diminished in splenectomised and 
congenital asplenic whereby switched memory B cells were present at normal frequency 
(Kruetzmann et al, 2003; Martinez-Gamboa et al, 2009). Therefore IgD+ memory B cells are 
likely generated outside GCs and potentially are under less stringent negative selection 
(Dörner, 2006). Currently, in-vivo mouse model in which human hemopoietic stem cells 
repopulation was studied clearly showed that development and induction of somatic 
hypermutation of human IgD+ memory B cells can occur in a T cell-independent manner 
(Scheeren et al, 2008).  
 
In our study the repopulation of pre-switch memory B cells (IgD+/ CD27+) after 
transient B cell depletion with rituximab showed significantly retarded repopulation of this B 
cell subtype.  Even 6 years after therapy the relative amount was diminished. At that time 
peripheral IgD+ memory B cells comprised still less than 5% of regenerated B cells compared 
to ~15% before rituximab therapy (P=0.0051). This longterm reduction of memory B cells 
particularly IgD+ memory B cells has been reported previously after rituximab in various 
diseases including SLE (Anolik et al, 2007), RA (Roll et al, 2006) and NHL (Nishio et al, 
2007). However, analysing the acquisition of mutations in these repopulated pre-switch 
memory B cells brought unexpected results. After a single course of treatment newly 
emerging IgD+ memory B cell showed a much delayed mutational behaviour.  80% of their Ig 
receptor showed no mutations at all during the first year after rituximab (Figure 4.11). In a 
prospective analysis of 3 patients before and 1 year after rituximab treatment we could not 
find any Ig receptor sequence with higher number (> 9 mutations/sequence) of somatic 
mutation (52% before therapy, P=0.0001) in the IgD+/CD27+ memory B cells. Patients with a 
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longer follow up after a single course of rituximab still had a remarkable delayed acquisition 
of somatic hypermutation in their IgD+ memory B cells Ig receptors which were significantly 
less even 6 years after treatment with only 27% highly mutated cells (Figure 4.10). We did 
find a time dependent increase in highly mutated sequences i-e 7.8% during 2nd year of 
regeneration (P=0.0001), 14% after 4 years (n=2) and 27%  highly mutated sequences after 
6years (n=3) rituximab treatment (P=0.0001) which argues for a retarded but continuously re-
establishing IgD+ memory compartment. These findings indicated that anti-CD20 mediated B 
cell depletion seems not only to delay the production of pre-switch memory B cells but also 
significantly affects the acquisition of mutations in the IgD+ memory B cell pool. These data 
argue for different requirements to undergo somatic hypermutations in comparison to class 
switched memory B cells. 
 
Post-therapy analysis of CDR3 length of regenerated IgD+ memory B cells revealed 
increased CDR3 length which also correlates well with elevated number of non-mutated VH 
gene rearrangements observed during repletion phase. A mean length of CDR3 region before 
therapy (Figure 4.13) was 43±0.89 bp which increased to 49±1.17bp during early repletion 
phase (P=0.0002). We observed a gradual decrease in CDR3 length along with mutational 
acquisition in these cells over a period of 6 years. Nevertheless, the mean CDR3 length was 
still significantly elevated (P=0.0080). Close observation of CDR3 lengths between 
unmutated and mutated sequences in our study showed that increased CDR3 length was 
restricted only to unmutated sequences which were more numerous after RTX (Figure 4.14).  
The CDR3 region is an active participant of antigen binding and the area of greatest diversity 
in the human Ig V region. Increased CDR3 length is particularly reported during ontogeny 
and decreases during antigen selection and somatic hypermutation (Souto-Carneiro et al, 
2005). Therefore our data may indicate that these cells are still under diversification and the 
impact of molecular mechanisms including TdT activity and selection process later on 
restricts a shorter CDR3 length. 
 
Reduced mutational frequency of IgD+ memory B cells after rituximab seems not to be 
related only to patients with rheumatoid arthritis or ongoing methotrexate therapy because we 
observed similar mutational pattern in a patient with SLE who had received no additional 
immunosuppressive treatment after rituximab directed B cell depletion (Figure 4.12). 
Therefore the effect of rituximab on pre-switch memory B cells seems to be a general effect 
and does not show any disease correlation.  
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To get more insight in mechanism regulating B cell recovery, we studied patients 
undergoing high dose chemotherapy followed by allogeneic and autologous stem cell 
transplantation. It was chosen because particular allogeneic stem cell transplantation inflicts 
broad impact on mesenchymal cells which can provide important environmental signals for 
optimal B cell development. Previous studies in stem cell transplant patients also have shown 
delayed recovery of overall memory B cells (Avanzini et al, 2005). Again we studied 
mutational acquisition in individual memory B cell receptors. Under these conditions class-
switched memory B cells also recovered with a normal high mutation rate, whereas the IgD+ 
memory B cell compartment showed again decreased mutations one year after stem cell 
transplantation compared to healthy donors. Interestingly, pre-switch B acquired more 
mutations after 1 year in these patients compared to patients after a single course of rituximab 
(figure 4.20). This argues for an additional unique effect of anti-CD20 antibodies on pre-
switch memory formation.   
 
The exact mechanism of action of rituximab mediated B cell depletion remains 
uncertain. Although the reactive B-cell memory is depleted to below the detection level in 
peripheral blood, changes in total Ig levels are minimal. B cell trafficking between RA lesions 
and secondary lymphoid organs are intrinsically involved in pathophysiology of rheumatoid 
arthritis (Voswinkel et al, 1999). Recently an ‘‘immune complex decoy hypothesis’’ and a 
‘‘road block hypothesis’’ (Taylor et al, 2007; Silverman et al, 2008) have been proposed to 
explain the effects of rituximab. ‘The immune complex decoy hypothesis’ suggests that 
rituximab-opsonized B cells may serve as decoys by engaging FcγR on effector cells to 
improve treatment efficacy. During Immune thrombocytopenic purpura (ITP) in which IgG 
anti-platelet antibodies promote platelet clearance via FcγR on macrophages, infusion of 
rituximab generates IgG-opsonized cells which bind to macrophages ultimately sparing 
platelets. On the otherhand in rheumatoid arthritis or SLE where immune complexes are 
present in joints and synovium, these rituximab-opsonized B cell decoys in blood stream and 
tissues may divert monocytes or macrophages from pathogenic interactions with tissue 
associated immune complexes and ultimately reduce disease activity without affecting 
autoantibody levels (Tayler et al, 2008). Rituximab affecting cellular trafficking lead to the 
formation of the so called ‘‘road block hypothesis’’ which postulates impaired trafficking of 
pathologic memory B cells and inflammatory cells in the joints by rituximab. The histological 
inspection of synovia of RA patients receiving rituximab has shown that some B cells persist 
in synovial tissue along with depletion of CD68+ macrophages and other invasive cells 
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affecting trafficking in synovia possibly by ‘road blocking’. In line with this idea of negative 
feedback, our data suggest that remnants of depleted B cells, including Ig receptors may have 
capacity to act as negative regulators on newly emerging B cells and may be particularly 
impeding IgD+ memory B cells formation and Ig receptor mutation acquisition in our 
rheumatoid arthritis patients’ cohort. Contrary to RTX, in allogeneic and autologous stem cell 
transplant patients, an additional eradication of pro-B cells takes place which affects 
subsequently different timings of repopulating B cells subsets. This may influence the less 
pronounced effect of delayed recovery of somatic hypermutation in IgD+ memory B cells in 
these patients.  
 
Contrary to the mutational pattern of IgD+ memory B cells after rituximab in our 
study, IgD-CD27+ memory B cells showed different results. Although the numeric 
replenishment of these recirculating class-switched memory B cells was also reduced after 
rituximab, we found no delay in quantitative acquisition of mutations in this memory B cell 
subset (Figure 4.15). These results indicate a normal development process with an unimpaired 
mechanism of mutational acquisition in class-switched memory B cells. The results of 
mutational pattern of class-switched memory B cells also indicated that the two memory 
subpopulations may have different regeneration sites with different requirements of cellular 
structures for mutational differentiation. However it cannot be excluded that the IgD+ memory 
B cell pool derives from early B cell progenitors whereas the class-switched memory B cell 
pool may derive partly from a memory pool reseeding from protected niches.  
 
In that context we analysed the distribution of mutations within the Ig gene more 
carefully in class switched memory B cells under rituximab treatment. Mutational targeting in 
characteristic RGYW/WRCY hotspot motifs (Dörner et al, 1998; Farner et al, 1999) has been 
described. This analysis was performed to address question whether any qualitative 
modulation occurred in the class-switched memory B cells during rituximab therapy. In 
accordance with previous findings by Palanichamy et al (Palanichamy et al, 2008), our data 
showed that post-therapy mutational targeting in RGYW/WRCY motifs were significantly 
increased as compared with that of pre-treatment (27% before rituximab vs. 43% after 
therapy, P=0.0003). This indicates that affinity maturation may operate differently in class-
switched memory B cells before and after B cell depletion. RGYW/WRCY motifs are 
believed to undergo somatic hypermutation particularly during T-B cell interactions in 
germinal center. The dependency of RGYW/WRCY motifs on T-B cell interaction was 
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further proven by studies of hyper-IgM patients who showed reduced mutational frequency in 
these motifs (Brezinschek et al, 2000). A possible explanation of reduced mutational targeting 
in RGYW/WRCY motifs before rituximab could be that T-cell independent B cell activation 
seems to be more dominant before therapy indicating that these processes are active in 
longstanding autoimmune diseases. 
 
The expressed Ig isotypes in class-switched memory B cells are mainly IgG and IgA. 
In rheumatoid patients before rituximab mediated transient B cell depletion the proportion of 
IgA and IgG expressing memory B cells was equal. However, in the repletion phase the 
percentage of IgA expressing memory B cells was strongly increased (Figure 4.22, 4.23). 
Previous studies monitoring serum Ig levels after rituximab therapy have indicated that IgG 
and particularly IgM serum levels were decreased after single and repeated courses of 
rituximab (Cambridge et al,2005; Roll et al, 2008) whereas serum IgA levels were shown to 
be maintained and only rarely decreased in one out of 34 studied patients (Popa et al, 2007). 
The fall in serum IgM and IgG levels was related to decrease in memory B cell formation 
after rituximab. Although it is still not clear why IgA expressing B cells are increased in our 
studied patients it may indicate that they derive from cells residing in secondary lymphoid 
organs where B cells depletion was not complete. Mechanistically, IgA class-switch 
recombination (CSR) occurs in Payer’s patches (PP) which are specialized clusters of 
lymphoid cells located in small intestine and also in non-lymphoid sites in the lamina propria 
(Stavnezer et al, 2009). IgA CSR in germinal centres within PP is T cell dependent. 
Additionally, different factors were studied to be involved in IgA CSR. Interestingly TGF-β is 
shown to be a key factor in IgA class-switching (Coffman et al, 1989; Sonoda et al, 1989). 
Activated B cells including plasma cells, T cells and dendritic cells are main source of TGF-β 
production (Stavnezer et al, 2009).  
 
In summary, the study has demonstrated a previously unknown delayed acquisition of 
somatic hypermutations in single Ig receptor VH gene rearrangements of IgD+ memory B cells 
after transient B cell depletion with anti-CD20 therapy in patients with rheumatoid arthritis. 
The results show a longterm effect of a single cycle of rituximab which was still evident even 
6 years after treatment. Rituximab seems to be particularly effective in targeting the 
development of IgD+ memory B cells and mutational acquisition in their Ig receptor since 
patients exposed to intensive chemotherapy and subsequently allogeneic/autologous SCT 
recover higher numbers of somatic hypermutations already within the first year after 
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treatment in that compartment.  On the otherhand, class-switched memory B cells showed a 
regular mutational pattern after rituximab directed B cell depletive therapy which was similar 
to stem cell transplant patients. However IgA expressing B cells dominated the class-switched 
memory B cell compartment during the B cell recovery phase. In addition antigenic pressure 
and/or selection are substantially reduced by rituximab therapy which is basically not seen in 
the class-switched memory B cell compartment. Taken together, these data are in line with the 
hypothesis that IgD+ memory B cells have distinct requirements for activating their 
mutational machinery whereas class-switched memory B cells recover with normal mutation 
rates early on. These results have implications in understanding the pathophysiology of 
memory B cell in rheumatoid arthritis and may be helpful in designing new targeted therapies.  
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7. Summary 
 
Diverse roles of B cells in the pathophysiology of rheumatoid arthritis are now well 
established. B cells contribute to autoimmunity by producing autoantibodies, processing 
autoantigen and the production of different cytokines which are involved in the inflammatory 
cascade. Therefore approaches to target B lymphocytes directly or indirectly are developed 
for clinical practice to treat autoimmune diseases including rheumatoid arthritis. Transient B 
cell depletion by rituximab (anti-CD20 antibody) has gained prime importance in recent 
years. Meanwhile anti-CD20 mediated transient B cell depletion therapy is now used with 
clinical efficiency in the treatment of patients with rheumatoid arthritis.  
 
Rituximab induces noteworthy changes in the homeostasis of peripheral B cell 
subpopulations during the repletion phase with emerging immature B cells in peripheral blood 
followed by normalization of the naïve B cell pool and a longterm delay in memory B cell 
subsets in patients with rheumatoid arthritis. Particularly IgD+CD27+ memory B cells 
repopulate very slowly during B cell regeneration. In a prospective clinical study, our 
laboratory has shown that the overall number of memory B cells correlates well to the 
duration of clinical response to rituximab. Little is known about the particular molecular 
changes in the memory B cell repertoire after rituximab therapy. To better understand 
peripheral memory B cell subsets, we explored in detail the somatic mutational frequency and 
pattern of Ig-VH3 gene rearrangements by using a single B cell sorting technique followed by 
nested PCR before and up to 6 years after rituximab therapy in 18 RA patients. We compared 
rituximab inflicted dynamics of mutational acquisition to memory B cell repopulation in 4 
healthy donors and 6 non RA patients undergoing high dose chemotherapy followed by 
autologous or allogeneic stem cell transplantation (SCT).  
 
 Firstly we analyzed the peripheral composition of memory B cell subsets. The 
phenotypic analysis of peripheral pre-switch (IgD+CD27+) and post-switch (IgD-CD27+) 
memory B cells did not reveal any quantitative differences in RA patients prior to B cell 
depletion therapy compared to healthy donors. However extending those studies in directly 
analysing the B cell immunoglobulin receptor from individual B cells of RA patients and 
healthy controls brought interesting results. Pre-switched and post-switched memory B cells 
showed a highly significant difference in the amount of mutations/sequence. The population 
of IgD+CD27+ memory B cells is comprised of non-mutated, low and highly mutated 
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(median= 9 mutations/ sequence) rearranged Ig receptors whereas the IgD-CD27+ memory B 
cell compartment shows quite uniformly highly mutated (median 18 mutations/ sequence) 
sequences indicating a significant difference between these two groups (mutational 
frequencies 3.83±0.19% vs. 7.1±0.53%; P=0.0001). 
 
Profound changes were noted in the re-emerging pre-switch memory B cells (IgD+/ 
CD27+) after transient B cell depletion with rituximab. These cells showed over a time period 
of 6 years after treatment with rituximab significantly delayed acquisition of mutations in Ig 
receptors on the single B cell level. One year after a single course of rituximab 84% of single 
repopulating IgD+/CD27+ B cells were unmutated and no highly mutated Ig-VH gene 
rearrangements were found(P=0.0001). Over time increasing numbers of mutations could be 
detected i-e 7.8% during 2nd year of regeneration (P=0.0001), 14% after 4 years (n=2). 
Nevertheless even 6 years after rituximab, VH mutations in IgD+ memory B cells were still 
reduced with 27% highly mutated sequences compared to 52% pre therapy(P=0.0001). Post-
therapy analysis of CDR3 length of regenerated IgD+ memory B cells revealed increased 
CDR3 length which also correlates well with elevated number of non-mutated VH gene 
rearrangements observed during repletion phase. In comparison patients undergoing high dose 
chemotherapy followed by allogeneic stem cell transplantation repopulated IgD+ memory 
cells earlier with higher numbers of mutations in IgD+ memory B cells. One year after 
transplantation Ig receptors showed already 22% highly mutated and 42 % unmutated VH 
rearrangements. These findings indicated that anti-CD20 mediated B cell depletion seems not 
only to delay the production of pre-switch memory B cells but also significantly affects the 
acquisition of mutations in the IgD+ memory B cell pool.  
 
In contrary to the mutational pattern of IgD+ memory B cells after rituximab class 
switched memory B cells repopulate in the periphery with quantitatively normal mutations in 
their Ig receptors. Although the numeric replenishment of these recirculating class-switched 
memory B cells was also reduced after rituximab, we found no delay in quantitative 
acquisition of mutations also an increased proportion of IgA expressing B cells in this 
memory B cell subset was detected. Our data showed that post-therapy mutational targeting in 
RGYW/WRCY motifs were significantly increased as compared with that of pre-treatment 
(27% before rituximab vs. 43% after therapy, P=0.0003) indicating that affinity maturation 
may operate differently in class-switched memory B cells before and after B cell depletion. 
These results indicate a normal development process with an unimpaired mechanism of 
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mutational acquisition in class-switched memory B cells. These data argue for different 
requirements to undergo somatic hypermutations in IgD+ memory B cells in comparison to 
class switched memory B cells. 
 
To conclude, our work has demonstrated for the first time a delayed acquisition of 
somatic hypermutations at single Ig receptor VH gene rearrangements of IgD+ memory B cells 
in comparison to class-switched memory B cells. These results demonstrate that IgD+ memory 
B cells are particularly susceptible to anti-CD20 treatment in patients with rheumatoid 
arthritis. In addition antigenic pressure and/or selection are substantially reduced by rituximab 
therapy which is basically not seen in the class-switched memory compartment. These data 
are in line with the hypothesis that IgD+ memory B cells have distinct requirements for 
activating their mutational machinery compared to class-switched memory B cells which 
recover normal mutations during regeneration phase. The results have implications in 
understanding the pathophysiology of memory B cell in rheumatoid arthritis and may be 
helpful in designing new targeted therapies.  
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Zusammenfassung  
 
B-Lymphozyten leisten unterschiedliche Beiträge zur Pathophysiologie der Rheumatoiden 
Arthritis. Sie produzieren Autoantikörper, präsentieren Autoantigene und schütten 
verschiedene Zytokine, die am proinflammatorischen Prozess beteiligt sind, aus. Aufbauend 
auf diesen Ergebnissen wurden in den letzten Jahren Therapien entwickelt, die gezielt B-
Lymphozyten ansteuern um direkt oder indirekt in den autoimmunen Krankheitsverlauf 
einzugreifen. Die zeitlich begrenzte B-Zell-Depletion mit Rituximab (anti CD20-Antikörper) 
hat dabei in den letzten Jahren einen hohen Stellenwert erlangt und wird im klinischen Alltag 
insbesondere bei der Behandlung von Patienten mit rheumatoider Arthritis  angewandt. 
 
Rituximab induziert im peripheren Blut bemerkenswerte Veränderungen in der Homöostase 
der B-Zell-Subpopulationen. Nach Therapie mit dem anti-CD20 Antikörper Rituximab 
beginnt die Repletionsphase mit der peripheren Aussaat von  transitionalen unreifen B-Zellen. 
Im weiteren Verlauf kommt es zu einer Normalisierung des naiven B-Zell-Pools. Das B-Zell 
Gedächtnis und in besonderem Maße die IgD+CD27+ Gedächtniszellen erholen sich nach 
Therapie nur langsam. In einer prospektiven klinischen Studie hat unsere Arbeitsgruppe 
gezeigt, dass die Gesamtzahl der Gedächtniszellen gut mit der Dauer der klinischen Antwort 
auf Rituximab korreliert. Es ist wenig über die speziellen molekularen Veränderungen 
innerhalb der Gedächtnis B-Zellen nach Rituximab Therapie bekannt. Um die Veränderungen 
im peripheren Blut zu verstehen untersuchten wir die somatische Mutationsfrequenz und das 
Muster der Ig-VH3 Gen Rearrangements, indem wir prä- und posttherapeutisch bei 18 
Patienten einzelne B-Zellen isolierten und den individuellen B-Zellrezeptor durch eine 
Einzelzell RT-PCR amplifizierten und sequenzierten. Wir verglichen das Mutationsmuster 
nach erfolgreicher B-Zelldepletion in den neu rezirkulierenden Gedächtnis B-Zellen mit dem 
Mutationsmuster von  vier Gesunden Blutspendern und sechs nicht-RA Patienten, die eine 
Hochdosis Chemotherapie mit anschließender autologer oder allogener 
Stammzelltransplantation erhalten hatten. 
 
Zunächst haben wir die Zusammensetzung der Gedächtniszellen im peripheren Blut 
analysiert. Der Phänotyp der peripheren prä-switch (IgD+CD27+) und post-switch (IgD-
CD27+) Gedächtniszellen zeigte keine quantitativen Unterschiede in RA-Patienten im 
Vergleich zu Gesunden. Bei der direkten Analyse des B-Zell Immunglobulin Rezeptors 
fanden sich jedoch zwischen  klassengeswitchten und ungeswitchten Gedächtnis B-Zellen 
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signifikante Unterschiede in der Anzahl der Mutationen in der variablen Region der Ig 
Rezeptors. Die Population der  IgD+CD27+ Gedächtniszellen beinhaltete sowohl nicht 
mutierte, wenig mutierte und stark mutierte (Median= 9 Mutationen pro Sequenz) 
rearrangierte Ig- Rezeptoren, wohingegen die IgD-CD27+ Gedächtniszellen einen 
durchgehend hoch mutierten (Median = 18 Mutationen pro Sequenz) Rezeptor aufwiesen. Der 
Unterschied zwischen beiden Gruppen war signifikant (Mutationsfrequenzen 3.83±0.19% vs. 
7.1±0.53%; P=0.0001). 
 
Grundlegende Veränderungen wurden bei den rezirkulierenden ungeswitchten 
Gedächtniszellen (IgD+CD27+) nach vorübergehender B-Zell Depletion mit Rituximab 
festgestellt. Diese Zellen wurden bis 6 Jahre nach Rituximab beobachtet und zeigten eine 
stark verzögerte Zunahme an Mutationen im Ig-Rezeptor. Ein Jahr nach einmaliger Gabe von 
Rituximab waren 84% der einzelnen zirkulierenden IgD+/CD27+ B-Zellen unmutiert. Zu 
diesem Zeitpunkt fanden sich keine stark mutierten Ig-VH3 Gen Rearrangements (P=0.0001). 
Mit zunehmendem Abstand zur B-Zell depletierenden Therapie konnten in der 
Repopulationsphase zunehmende Zahlen an Mutationen in den B-Zell Ig Rezeptoren 
festgestellt werden. Beispielsweise waren während des 2. Jahres der Regeneration (P=0.0001) 
7.8%, sowie nach 4 Jahren nur 14% der Ig Rezeptoren mutiert. Sogar 6 Jahre nach 
Behandlung, waren VH Mutationen in IgD+ Gedächtniszellen noch deutlich vermindert. 
Selbst nach dieser Zeit fanden sich in der prä-switch Gedächtnispopulation nur 27% 
hochmutierte Sequenzen während vor der passageren B-Zelldepletion  52% ein hohe Zahl an 
Mutationen trugen (P=0.0001). Die posttherapeutische Analyse der CDR3 Länge der 
regenerierten IgD+ Gedächtniszellen ergab eine erhöhte CDR3 Länge, die signifikant mit der 
Anzahl der nicht mutierten VH Genrearrangements während der Repletionsphase korreliert. 
Interessanterweise regenerierten Patienten nach Hochdosis Chemotherapie und allogener 
Stammzelltransplantation ihre IgD+ Gedächtniszellen mit einer deutlich höheren Anzahl an 
Mutationen. Ein Jahr nach Transplantation zeigten die Ig Rezeptoren schon 22% hoch 
mutierte und 42% unmutierte VH Rearrangements. Das zeigt, dass eine gegen CD20 
gerichtete Behandlung nicht  nur eine Verzögerung der Produktion der ungeswitchten 
Gedächtniszellen zur Folge hat, sondern darüber hinaus einen signifikanten Effekt auf die 
Mutationsrate im präswitch Gedächtnis B-Zellpool besitzt. 
 
Im Gegensatz zum Mutationsmuster der IgD+ Gedächtniszellen regenerierten die 
klassengeswitchten Gedächtniszellen nach anti-CD20 Depletion im peripheren Blut mit 
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quantitativ normalen Mutationen im Ig Rezeptor. Interessanterweise fand sich allerdings eine 
Änderung der exprimierten Isotypen mit deutlicher Dominanz IgA exprimierender B Zellen. 
Weitere Analysen der klassengeswitchten Gedächtnis B-Zellen zeigen außerdem eine 
Therapie induzierte qualitative Veränderung dieses B-Zellpools. So waren posttherapeutisch 
die Mutationen in bestimmten T-Zell abhängigen Mutationshotspots, dem RGYW/WRCY 
Motiv, signifikant vermehrt (Mutationstargeting  vor Therapie 27% vs. 43% nach Rituximab, 
P=0.0003). Dies weist darauf hin, dass die Mechanismen der Affinitätsreifung im 
klassengeswitchten B-Zellgedächtnis vor und nach B-Zelldepletion unterschiedlich 
funktionieren. Der Mutationsmechanismus selbst ist allerdings in diesen Zellen quantitativ 
nicht eingeschränkt.   
 
Zusammenfassend zeigt unsere Arbeit zum erstem mal, dass es nach einer passageren B-
Zelldepletion mit anti-CD20 Antikörpern zu einer über Jahre hinweg nachweisbaren 
ausgeprägten Verzögerung in der Aquisition von somatischen Mutationen in rearrangierten 
VH Genen der IgD+ Gedächtniszellen kommt. Demgegenüber erholt sich das 
klassengeswitchte B-Zellgedächtnis mit uneingeschränkter Zahl von Mutationen im Ig 
Rezeptor. Diese Resultate zeigen, dass anti-CD20 gerichtete Therapien in besonderem Maße 
IgD+ Gedächtniszellen beeinflussen. Der Selektionsdruck durch Antigene und/oder die 
Selektion der Ig Rezeptoren erscheint unter diesen Bedingungen speziell bei IgD-Gedächtnis 
B-Zellen reduziert. Die Daten unterstützen die Hypothese, dass prä-switch Gedächtnis B-
Zellen im Vergleich zu post-switch Gedächtnis B-Zellen andere Bedingungen für die 
Aktivierung der Mutationsmaschinerie benötigen. Die Resultate eröffnen neue Wege für das 
Verständnis der Pathophysiologie der B-Zell Gedächtnisentwicklung und können helfen neue 
zielgerichtete Therapien zur Behandlung von Autoimmunerkrankungen zu konzipieren.      
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Abbreviations 
ACR   american college of rheumatology 
ADCC   antibody dependent cellular cytotoxicity 
ADA   Adalimumab 
AID   activation induced cytidine deaminase 
ANCA   anti-neutrophils cytoplasmic antibody 
APC   antigen presenting cell 
BAFF   B cell activating factor 
BCR   B cell receptor 
BCMA  B cell maturation antigen 
BLyS   B lymphocyte stimulator 
bp   base pair 
C   constant 
cDNA   complementary DNA 
CDC   complement dependent cytotoxicity 
CDR   complementary determining region 
CSR   class switch recombination 
CZP   Certolizumab 
D   diversity gene 
DAS   disease activity score 
DMARD  disease modifying anti rheumatic drug 
DNA   deoxyribonucleic acid 
DSB   double strand break 
ETN   Etanercept 
FCS   fetal calf serum 
FR   framework region 
FACS   fluorescence activated cell sorting 
GC   germinal centre 
GLM   Golimumab 
HLA   human leukocyte antigen 
IL   interleukin 
IFN-γ   interferon gamma 
IFX   Infliximab 
Ig   immunoglobulin 
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Ig-H   immunoglobulin heavy chain 
IgL   immunoglobulin light chain 
IgR   immunoglobulin receptor 
IL   interleukin 
ITP   immune thrombocytopenia purpura 
J   joining gene 
Jk   kappa light chain joining gene 
Jλ   lambda light chain joining gene 
MTX   Methotrexate 
mRNA  messenger RNA 
PB    peripheral blood 
PBMCs  peripheral blood mononuclear cells 
PCR   polymerase chain reaction 
PEG   polyethylene glycol 
R   purine 
RA   rheumatoid arthritis 
RAG   recombination activating gene 
RF   rheumatoid factor 
R/S   replacement to silent mutation 
RT-PCR  reverse transcriptase polymerase chain reaction 
RTX   Rituximab 
SCT   stem cell transplant 
SHM   somatic hypermutation 
SLE   systemic lupus erythematosus 
TD   T cell dependent  
TI   T cell independent  
TLR   toll like receptors 
TNF   tumor necrosis factor 
TNFR   tumor necrosis factor receptor 
V   variable  
VH   heavy chain variable region 
VL   light chain variable region 
Y   pyrimidine 
W   adenosine or thymidine 
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